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Limitierend für pharmakologische Therapien ist oft die Unfähigkeit des Wirkstoffes, 
biologische Membranen zu überwinden, weswegen häufig Transportmoleküle wie z.B.  
zellpenetrierende Peptide (CPPs, cell penetrating peptides) benutzt werden. Von den 
über 100 beschriebenen CPPs wurde bisher nur eine kleine Anzahl systematisch 
verglichen, was die Auswahl des „richtigen“ CPPs für eine Anwendung erschwert. 
Ziel dieser vorliegenden Arbeit war es, das pro-apoptotische Peptid KLA mittels CPPs 
spezifisch in Krebszellen zu transportieren. Untersucht wurden: (I) Verschiedene CPPs 
in unterschiedlichen Zelltypen zur Selektion der „besten“ CPPs; (II) Der Einflusses des 
CPP C-Terminus auf die Internalisierung und zelluläre Verteilung; (III) Der zelluläre 
KLA-Transport mittels CPPs via einer nicht-kovalenten Administration.  
22 verschiedene CPPs wurden in sieben Zelltypen untersucht, wobei Toxizität, 
Zellaufnahme und zelluläre Lokalisation mittels Fluorescein markierten CPPs in 
Fluoreszenzspektroskopie und konfokaler Mikroskopie betrachtet wurden. Abhängig 
von der Zellaufnahme wurden die CPPs in drei Gruppen klassifiziert. Die Untersuchung 
carboxylierter und carboxyamidierter CPP C-Termini ergab, dass in den meisten Fällen 
ein Carboxyamid die zelluläre Aufnahme begünstigte.  
Drei CPPs (MPG, Penetratin und Integrin) wurden ausgewählt, um das pro-apoptotische 
KLA Peptid in zwei Krebszelllinien (MCF-7 Brustkrebszellen und leukämische 
RAW264.7 Makrophagen) im Vergleich zu Fibroblasten (Cos-7) nicht-kovalent zu 
transportieren. Der erfolgreiche KLA-Transport hing vom CPP, dessen C-Terminus und 
der Zelllinie ab. Die Analyse der Viabilität nach CPP:KLA Administration ergab, dass 
MPG-CONH2:KLA (1:2) toxisch für Makrophagen und Brustkrebszellen, aber nicht für 
Fibroblasten war. Die Toxizität konnte der Apoptose zugeordnet werden. 
Die vorliegende Arbeit liefert wichtige Informationen über die Auswahl des passenden 
CPPs für den nicht-kovalenten Transport des pro-apoptotischen KLA-Peptids. 
 





Limitations in a pharmacological therapy are often due to the inability of drugs to 
overcome the cellular membrane and therefore transporting molecules are being used, 
e.g. cell penetrating peptides (CPPs). Only a few of the over 100 described CPPs have 
been compared systematically making the choice of “the” CPP for a given application 
difficult. 
The goal of the presented work is the CPP mediated delivery of the pro-apoptotic 
peptide KLA in breast cancer cells as proof of principle for a therapeutical application. 
Analysed were (I) Different CPPs in various cell types to select the “best” one, (II) The 
influence of the CPP C-termini on uptake and localisation, (III) The cellular KLA 
delivery via a non-covalent CPP administration. 
22 CPPs were compared in seven cell types thereby looking at toxicity, cellular uptake 
and subcellular localisation using fluorescein labelled CPPs for fluorescence 
spectroscopy and confocal microscopy. The resulting uptake information allowed the 
classification of the CPPs in three main groups. The evaluation of carboxylated and 
carboxyamidated CPP C-termini revealed that a carboxyamide mostly enhanced the 
cellular CPP uptake.  
Three CPPs were selected (MPG, penetratin and integrin) to deliver the pro-apoptotic 
KLA peptide in two cancer cell lines (breast cancer MCF-7 cells and RAW264.7 
macrophages) compared to fibroblasts (Cos-7) via the non-covalent strategy. A 
successful KLA delivery depended on the applied CPP, its C-terminus and the used cell 
line.  
The biological activity of the pro-apoptotic KLA peptide was determined via the cell 
viability (MTT assay). The co-incubation of MPG-CONH2:KLA (1:2) was able to 
induce toxicity in breast cancer cells and leukaemic macrophages, but not in fibroblasts. 
The viability reductions were then assigned to apoptosis. 
This work provides important information for the choice of an adequate CPP for the 
pro-apoptotic KLA peptide delivery and presents the advantage of the non-covalent 
delivery strategy. 
 
Keywords: cell penetrating peptide, KLA peptide, pro-apoptotic, non-covalent, peptide 
delivery
1. INTRODUCTION  3 
 
1. INTRODUCTION 
The observation and modulation of intracellular processes in the context of 
physiological and molecular-pharmaceutical studies is the basis of a specific and 
targeted development of active pharmaceutical agents. Necessary for that end as well as 
for an effective pharmacotherapy, a sufficient concentration of the biological active 
substance is needed at the site of action, which therefore requires an efficient 
internalisation. One of the main obstacles is the translocation over the cell membrane. 
Furthermore, depending on the target site, pharmaceuticals need to be distributed to 
different parts of the body while overcoming additional absorption barriers (e.g. blood-
brain barrier). 
1.1. Problems of Drug Delivery 
The cell membrane protects the cell from the invasion of pathogens and other harmful 
molecules and is needed for the maintenance of the cells inner homeostasis, resulting in 
a well controlled import and export. Only small lipophilic molecules (< 600 Da) are 
able to pass the membrane by passive diffusion, whilst bigger ones have to be 
transported in energy-dependent and independent events [reviewed in (Sawant et al., 
2009)]. 
For a better understanding of intracellular biochemical processes, scientists need to 
translocate various molecules into living cells whilst influencing the cell as little as 
possible in its viability and homeostasis. Different methods have been developed, which 
either permeabilise the plasma membrane for a short amount of time or make use of 
transport molecules, so called carriers. 
A method to overcome the plasma membrane is the microinjection of molecules by 
glass needles into the cytoplasm or nucleus (Capecchi, 1980). Cell plasma membrane 
permeabilisation is done by electroporation (Knight et al., 1986; Rols, 2006) or 
sonoporation (Wyber et al., 1997), in which an externally applied electrical field or 
ultrasonic sound induces pores in the membrane, respectively. Furthermore, pore 
forming molecules (Walev et al., 2001), laser irradiation (Zeira et al., 2003) or the 
“gene pistol” (Wells, 2004) can be used to overcome the cell membrane. These methods 
are unfortunately mostly inapplicable to the therapeutic utilisation for humans and are 
therefore primarily used in laboratories. 
In pharmacology, carriers are therefore highly important and used to transport cargoes 
efficiently to the site of action, which can be a specific cell type, cell compartment or 
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cellular component. In contrast to free, unbound small molecules that passage the cell 
membrane mostly by diffusion or unspecific, adsorptive pinocytosis, carrier-bound 
molecules mostly internalise by receptor-mediated endocytosis. Examples of carriers 
include pH sensitive liposomes and polymers, cationic liposomes, lipids and polymers, 
viral vectors, polymeric nanoparticles and fusogenic peptides (Rawat et al., 2007). 
1.2. Cell Penetrating Peptides 
An increasing popular class of membrane translocating agents is represented by the cell 
penetrating peptides (CPPs), also called protein transduction domains (PTDs) [reviewed 
in (Deshayes et al., 2005; Jarver et al., 2006)]. CPPs are able to translocate over the 
cellular membrane into different cell types in vitro (cell lines, primary cultures or 
tissues) and have even been applied in vivo (mouse, rat) transporting a range of different 
molecules e.g. nucleic acids, PNA, peptides, proteins, liposomes and nanoparticles 
[overview: (Dietz et al., 2004; Langel, 2002; Lindsay, 2002; Sawant et al., 2009)]. 
Work in the CPP area stemmed from the discovery that the third helix of the 
Antennapedia homeodomain, pAntp (43–58) (Derossi et al., 1994) and the trans-
activating transcriptional activator, Tat, a protein encoded by human immunodeficiency 
virus-1 (HIV-1) (Frankel et al., 1988; Green et al., 2003), can cross biological 
membranes. Up to the turn of the millennium, the number of peptides assigned to the 
family of CPPs has increased tremendously (Lindgren et al., 2000). Nowadays, they can 
be divided into three classes: protein-derived peptides, model peptides and designed 
peptides (Zorko et al., 2005). Protein-derived CPPs usually comprise the minimal 
effective sequence segment of the parent translocation protein and are also known as 
protein transduction domains or membrane translocation sequences. Examples are the 
Tat peptide (48–60) derived from the 86-mer Tat protein (Vives et al., 1997) or 
penetratin (43–58) derived from the homeodomain Antennapedia of Drosophila (Joliot 
et al., 2008). Model CPPs comprise sequences designed with the aim of producing well-
defined amphipathic α-helical structures, or mimicking the structures of known CPPs. 
Examples are the model amphipathic peptide (MAP) (Oehlke et al., 1998) or 
polyarginine sequences (Futaki et al., 2001). Designed CPPs are usually chimeric 
peptides containing a hydrophilic and a hydrophobic domain of different origins, such 
as transportan, a fusion peptide of galanin and mastoparan (Pooga et al., 1998a).  
However, no unambiguous definition of CPPs has been proposed, only common 
features have been agreed on; such as (I) CPPs carry a net positive charge at 
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physiological pH and (II) CPPs facilitate the rapid translocation of molecules across 
cellular membranes. Generally, they comprise less than 30 amino acids and contain 
between approximately 17 % [e.g. hCT(9-32)] to 100 % [polyarginines] positively 
charged amino acids. With some exceptions such as polyarginine and integrin, most 
CPPs are amphipathic. Some of them acquire amphipathic characteristics when 
adopting an α-helical structure, as for instance the model peptide MAP (Oehlke et al., 
1998), while others have distinct hydrophobic and hydrophilic parts, such as transportan 
(Yandek et al., 2008). 
As mentioned, CPPs reveal remarkable properties of cell penetration either on their 
own, or as conjugates with a range of other types of biomolecules [reviewed in 
(Lindsay, 2002)]. However, the endocytic mechanism used - clathrin-mediated 
endocytosis (Richard et al., 2005), caveolae-mediated endocytosis (Ferrari et al., 2003; 
Fittipaldi et al., 2003) or macro-pinocytosis (Kaplan et al., 2005; Wadia et al., 2004) - 
defines the migration of these peptides into cells and depends on parameters such as the 
nature of the cationic agent itself and complex formation with cargo, as well as the 
nature and distribution of proteoglycans expressed on the cell surface (Duchardt et al., 
2007; Poon et al., 2007). Most likely CPPs utilise multiple internalisation mechanisms 
in combination (Duchardt et al., 2007). Besides the translocation by endocytosis, it is 
thought that they are also able to overcome the cell membrane by energy-independent 
mechanism, such as micelle and pore formation (Deshayes et al., 2004).  
1.3. The CPPs of This Study 
In this study, 22 different CPPs were chosen as representative cadidates from the three 
different CPP classes (Table 1, page 29). 
SynB1 derives from the antimicrobial peptide protegrin, which was isolated from 
porcine leukocytes and acts against a broad spectrum of microorganisms (Steinberg et 
al., 1997). The amphipathic, linear SynB1 is able to pass biological membranes as well 
as the blood brain barrier and is therefore involved in the development of peptide-
conjugated pharmaceuticals (Rousselle et al., 2000).    
Polyomavirus Vp1 originates from the capsid protein VP1 of this virus. It is able to 
translocate into the nucleus, because the peptide contains a nuclear localisation 
sequence (NLS) as well as a DNA-binding motif (Chang et al., 1993; Murray et al., 
2001). 
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Penetratin results from the Drosophila homeoprotein Antennapedia. Homeoproteins 
belong to the trans-activating factors and were described first in Drosophila 
melanogaster (Gehring, 1987). They consist a DNA-binding motif, the 60 amino acid 
long homeodomain, structured in three α-helices (Qian et al., 1989). The amphipathic 
CPP penetratin (amino acid 43-58) derives from the third helix of this homeodomain 
(Derossi et al., 1994). 
Tat, also called HIV-1 Tat-(48-60), is the most frequently used CPP and stems from the 
transcriptional activator protein of HIV-1, is known to internalise into cells as well as 
the nucleus (Frankel et al., 1988) and can be used as a vehicle for heterologic proteins 
(Fawell et al., 1994). The cell penetrating peptide Tat contains a cluster of basic amino 
acids 49-58 with a nuclear localisation sequence (Ruben et al., 1989).   
Bac1-15 originates from Bac7, which is a bactenicin isolated from the granules of 
bovine neutrophils (Gennaro et al., 1989). Its antimicrobial activity results from the 
increase in membrane permeability resulting in the inhibition of the bacterial respiration 
and ATP (adenosine-5'-triphosphate)-synthesis and therefore also of the protein 
biosynthesis (Skerlavaj et al., 1990). Cationic Bac1-15 was found in the cytoplasm as 
well as the nucleus (Sadler et al., 2002).  
NF-κB is a positively charged NLS of the nucleus factor kappa B, which is involved in 
the regulation of cellular and viral genes (Lenardo et al., 1989) and exhibits cell 
penetrating properties (Ragin et al., 2002). 
SV40, a short, seven amino acid long NLS, stems from the Simian Virus 40 large 
tumour antigen and is able to promote the nuclear accumulation of usually cytoplasmic 
proteins like the β-galactosidase (Kalderon et al., 1984). 
HATF3 is the NLS of the basic region of the human activating transcription factor 
(ATF)-3 (Hai et al., 1989) and internalises into the cell probably by endocytosis (Ragin 
et al., 2002). 
hCT(9-32) derives from the C-terminal domain of human calcitonin, a hormone 
involved in the regulation of the calcium and phosphate balance (Copp, 1970). In 
comparison to the other CPPs its charge is relatively low at physiological pH. After the 
penetration of the cell membrane it is found in the cytoplasm in a punctuated pattern, 
but not in the nucleus (Trehin et al., 2004). 
Rev, also called HIV-1 Rev-(34-50), originates from the trans-activating Rev protein of 
HIV-1 and contains a nuclear localisation sequence (Cochrane et al., 1990) as well as a 
RNA (ribonucleic acid)-binding motif (Bohnlein et al., 1991). 
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pVEC is a peptide stemming from murine, endothelial cadherin, which is a 
transmembrane protein mediating cell contact between neighbouring cells and 
anchoring the actin cytoskeleton with the plasma membrane (Huber et al., 1996). The 
peptide sequence consists of 13 amino acids, which are usually located near the cell 
membrane and five hydrophobic amino acids of the C-terminus of the transmembrane 
region (Elmquist et al., 2001). 
Integrin derives from the hydrophobic region of the cytoplasmic part of the human 
transmembrane protein integrin β3. So far, its cell penetrating properties were described 
being cell type unspecific (Hawiger, 1999). 
DPV6 (Diatos Peptide Vector) stems from PDGF (platelet-derived growth factor), 
belongs to the human Vectocell® penetrating peptides and can interact with 
aminoglycans, like heparin, on the cell surface. It has been described as non-toxic in 
vitro and in vivo and was found in the cytoplasm together with the cargo protein 
maleimid without the detection of a nuclear localisation (De Coupade et al., 2005). 
S413PV is from a 13 amino acid sequence of the dermaseptin S4 peptide, which has cell 
penetrating properties attached to the NLS of SV40 large T antigen (Hariton-Gazal et 
al., 2002). Dermaseptin was isolated from the skin of the frog Phyllomedusa bicolor, 
adopts a α-helical conformation and inhibits the growth of a number of pathogenic 
microorganisms (Mor et al., 1994). 
Transportan consists of amino acids from the neuropeptide galanin and the wasp toxin 
mastoparan linked via a lysine residue. During the cellular uptake transportan is found 
first at the outer membrane and cytoplasmic membrane structures, and later at the 
nuclear membrane and inside the nucleus, where it condenses in sub-structures, 
probably in the nucleoli (Pooga et al., 1998a). 
Pep-1, also known as Chariot™, belongs to the newly constructed peptides. It has a 
hydrophobic tryptophan-rich domain to interact with proteins on the cell membrane and 
a hydrophilic, lysine-rich domain, the NLS of SV-40 large T-Antigen, to reach the 
nucleus fast. Pep-1 is able to penetrate various cell lines and accumulates fast in the 
nucleus (Morris et al., 2001). 
MPG (FP-NLS MPG, model amphipathic peptide) is a synthetic peptide, in which the 
hydrophobic domain of the fusion protein gp41 of HIV was combined with the 
hydrophilic domain of the SV40 large T antigen NLS (Morris et al., 1997). MPG is able 
to transport single and double-stranded oligonucleotides into the nucleus independent of 
endosomal pathways (Vidal et al., 1998). 
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MAP is a designed, amphipathic peptide containing lysine, leucine and alanine residues 
(Oehlke et al., 1996). Its penetration was reported being cell type independent and it 
was found in the nucleus (Oehlke et al., 1998). 
Poly-P, a peptide containing many prolines, is found in the cytoplasm after peptide 
incubation and is reported to show no toxic effects even at high concentrations 
(Fernandez-Carneado et al., 2004). 
R7 and R9, the poly-arginine peptides, are the only non-amphipathic peptides, which 
are able to pass the cell membrane. R9 is able to translocate 100-times more efficient 
than Tat and both peptides are even more resistant to proteases (Wender et al., 2000). 
pVEC-scrambled is the mixed sequence of pVEC and used as a negative control in this 
study, since it is unable to pass the cell membrane (Elmquist et al., 2003). 
1.4. Strategies of CPP Delivery 
1.4.1. Covalent Delivery 
The main purpose of CPPs is their use as delivery vehicle for biological active 
substances into living cells. For that, the cargo is usually attached to the CPP either by 
covalent linkage or tandem synthesis/expression, when the cargo is a peptide or protein 
(Gait, 2003; Nagahara et al., 1998). Here the final localisation of the chimeric molecule 
depends on both cargo and carrier.  
CPPs have been shown to efficiently improve intracellular delivery of various 
biomolecules, including plasmid DNA, oligonucleotides, siRNA (short interfering 
RNA), PNA (peptide nucleic acid), proteins and peptides, as well as liposome 
nanoparticles, into cells both in vivo and in vitro. Short synthetic CPPs have been 
designed to overcome both extracellular and intracellular limitations, trigger the 
movement of a cargo across the cell membrane into the cytoplasm and improve its 
intracellular trafficking, thereby facilitating interactions with the target (Brasseur et al., 
2010; Sawant et al.).  
When CPPs are used to transport other peptides, they are usually synthesised 
continously. Snyder and colleagues synthesised a tumour suppressor p53-derived 
peptide linked to Tat and were able to restore p53 protein activity in cancer cells 
(Snyder et al., 2004). They showed that the CPP did not hinder the therapeutical 
effectiveness of the p53-derived peptide and that it was proteolytically stable.  
If the conjugates are longer than about 50 amino acids, they are either genetically 
expressed in tandem or chemically conjugated. One of the first reports stated the 
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120 kDa β-galactosidase protein expressed in tandem with the Tat peptide was able to 
translocate in all tissue of the mice and even passaged the blood-brain barrier (Schwarze 
et al., 1999).  
Chemical conjugation through disulfide bond formation is particularly interesting. It can 
form between thiol groups of cysteine residues and will be reduced when entering the 
cytoplasm due to the intracellular redox environment followed by the release of the 
cargo (Hallbrink et al., 2001). Efficient and specific coupling, thereby preventing the 
formation of homodimers, can be done by the use of 2-pyridinesulfenyl (SPyr)-
protected cysteine-containing peptides with thiol-unprotected peptides (Schulz et al., 
2000). Unfortunately, due to the lack of glutathione and therefore thiolate anions, 
disulfide cleavage is disfavoured in the acidic endosome, but happens at the cell surface 
and may happen in the early endosome (Feener et al., 1990; Jones, 2007). This needs to 
be taken into consideration, since the CPPs are often endocytosed. 
Coupling proteins or peptides to CPPs with a short proteolytic cleavage site in between 
is another possibility. Recombinant Tat-delivered alpha B-crystallin, a small heat shock 
protein, was delivered into cells and proteolytically cleaved by matrix 
metalloproteinase-1 (MMP-1), which then could be blocked by the treatment with a 
MMP inhibitor (Yang et al., 2011). MMP-2 and -9 activities are associated with tumour 
invasion and metastasis (Egeblad et al., 2002). A specific linker, predominantly 
sensitive to these MMPs, has been used to attach a short cationic CPP sequence to 
neutralising anions (Olson et al., 2009). When the molecule is cleaved by MMP-1 
and -9, the masking anion is detached releasing the cell membrane adhesive CPP 
sequence as well as the cargo and promoting cellular uptake of both. Tsien’s group used 
dendrimers to display many activatable CPPs, which transport magnetic resonance and 
fluorescent probes for tomographic imaging as well as superficial intraoperative 
guidance during surgery. They were able to detect very small tumours and metastasis of 
200 µm. This potential diagnostic agents is promising, since it can be used (I) for a wide 
range of tumours, (II) for all tumour markers, (III) for whole-body scanning as well as 
(IV) for precise, fluorescence-guided surgery. 
One main purpose of CPPs is the delivery of oligonucleotides for a therapeutical 
application. For example, RNA interfering (RNAi) technology is a powerful technique 
for post transcriptional gene silencing, in which short interfering double stranded (ds) 
RNAs (siRNAs) are loaded into the RNA-induced silencing complec (RISC) siRNAi 
complex in  the cytoplasm, which then recognises and degrades target mRNA. The 
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delivery of siRNAs remains a problem, since they are highly negatively charged and 
therefore rejected by the cell membrane. Eguchi and Dowdy linked a RNA-binding 
domain to a CPP, thereby masking the negative charge of the siRNA and were able to 
completely knockdown the target gene in the whole cell population in over 30 cell types 
including primary cells [reviewed in (Eguchi et al.)]. Their peptide transduction 
domain-dsRNA binding domain (PTDDRBD) represents a promising tool for RNAi 
therapy in the future. 
Furthermore, uncharged oligonucleotide analogues, peptide nucleic acids (PNA) and 
phosphorodiamidate morpholino oligomers (PMO, morpholino) are widely used for 
antisense applications, such as steric block ONs for the inhibition of translation. In 
principle, PNAs can be coupled to CPPs either by synthesis in tandem (Simmons et al., 
1997) or through conjugation by thioether or disulfide linkages (Abes et al., 2007; 
Moulton et al., 2004). Here as well the disulfide linkage is very popular and was first 
used by Pooga et al. (Pooga et al., 1998b), who linked PNA, complementary to the 
human galanin receptor type 1 mRNA, to transportan and penetratin suppressing the 
expression of functional galanin receptors. Thioether, disulfide or amide conjugated 
CPP-PMOs have similar nuclear antisense activity (Moulton et al., 2004), but the amide 
linkage might be advantageous, since it requires only one step synthesis and purification 
in comparison to a two step process. In addition, it was found to be more stable in 
human serum than disulfide-linked CPP-PMO (Youngblood et al., 2007). One of the 
most promising CPP-PMO conjugates is used in the treatment of Duchenne muscular 
dystrophy. Avi Biopharma, a company working with CPPs, uses 6-aminohexanoic acid 
spaced oligoarginine [(R-Ahx-R)4] for in vivo steric block splicing correction in the 
treatment of Duchenne Muscular dystrophy (Wang et al., 2010). Further CPPs have 
even made it into clinical trials. CellGate Inc. initiated phase II clinical trials with 
cyclosporine linked to polyarginines in 2003 to treat patients with psoriasis (Rothbard et 
al., 2000; Smith et al., 2003). A phase IIa clinical trial is now in progress in patients 
suffering from acute myocardial infarction for testing PKC (protein kinase C) peptidic 
inhibitors known to be cardioprotective (Bates et al., 2008). In particular the δ-PKC 
inhibitor KAI-9803 (also known as δ-V1-1) leads to reduced damages in 
cardiomyocytes (> 60 % infarct size reduction) and endothelial cells after an ischemic 
insult (Inagaki et al., 2003). 
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Although conjugation methods offer several advantages for in vivo applications, 
including rationalisation and control of the CPP-cargo, they remain limited from the 
chemical point of view, as they risk altering the biological activity of the cargoes. 
1.4.2. Non-Covalent Delivery 
The non-covalent delivery of biomolecules has been reported for several CPPs (Morris 
et al., 2008). It is advantageous, because it simplifies conjugation protocols and 
different cargoes can be delivered without the adjustment of them (although the mixing 
ratio might need some consideration). Furthermore, the non-covalent delivery decreases 
the likelihood of unwanted influences of the CPP on cargo activity as well as of the 
cargo on the cell penetrating properties of the CPPs.  
Different approaches for gene-delivery have been used. Peptides, which are able to 
complex with DNA, associate with peptides that facilitate endosomal escape, such as 
the fusion peptide of HA2 subunit of influenza haemagglutinin (Wagner et al., 1992). 
Other successful gene carriers are MPG (Morris et al., 1999) or the synthetic peptide 
analogue GALA (Gottschalk et al., 1996). Furthermore, Pep-1 was able to deliver 
peptides and proteins non-covalently in vitro (Morris et al., 2001) and in vivo (Gros et 
al., 2006). MPG formed stable non-covalent complexes with siRNA and delivered it 
efficiently into the nucleus of mammalian cells, for which the NLS was essential for 
nuclear delivery, but not for cytoplasmic targeting (Simeoni et al., 2003). Electrostatic 
and hydrophobic interactions are responsible for stable complex-formation of Pep-1 and 
MPG with oligonucleotides or peptides and proteins (Morris et al., 2001; Simeoni et al., 
2003).   
The novel CPP Rath was also able to deliver proteins and nucleic acids in a 
temperature-independent mechanism hereby avoiding endosomal entrapment (Bais et 
al., 2008). It was also capable of delivering large antibodies into primary cells, which is 
thought to be more difficult than the delivery into immortalised cell lines and was non-
cytotoxic at high concentrations (75 µM). Another approach is the inclusion of RNA 
binding domains in the Tat sequence, which then specifically recognises a short RNA 
sequence. The siRNA cargo is designed including the matching RNA sequence and is 
transported into the cells by complex formation (Endoh et al., 2009). The attachment of 
the CPP to the cargo can also be done by using the interactions of avidin and biotin-CPP 
constructs (Pooga et al., 2001). 
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1.4.3. CPP-Modified Liposomes 
Liposomes for the carriage of water-soluble drugs and micelles delivering poorly 
soluble therapeuticals are probably the most popular and well-investigated drug carriers 
(Torchilin, 2005; Torchilin, 2007). When Tat was incorporated in liposomes via a 
spacer molecule, which allowed the Tat peptide to interact with the cell surface, cells 
displayed an enhanced uptake (Pittet et al., 2006). Furthermore, the number of CPP 
molecules (Tat and penetratin) attached to the liposomal surface was proportional to the 
translocation and was dependent on peptide and cell type used. The conjugation of 
CPPs (such as R8) to liposomes was found to enhance their uptake into airway cells 
upon inhalation (Cryan et al., 2006). The incorporation of Tat into micelles was used to 
deliver anticancer drugs to acidic, solid tumours (Sethuraman et al., 2007). 
Besides the incorporation of CPPs in liposomes and micelles, they have been used for 
the modification of solid lipid nanoparticles (no inner aqueous space) and were able to 
enhance the gene transfection in vitro and in vivo compared to polyethylenimine 
nanocarriers (Suk et al., 2006). 
Surprisingly, Tat peptide-modified liposomes (Tatp-lipoplexes), which were prepared 
with small amounts of cationic lipids, complexed with DNA showing higher 
transfection and less toxicity than Lipofectamine® in mouse fibroblasts and cardiac 
myocytes. When injected intratumourally, Tat-liposome-DNA complexes showed 
efficient transfection (Torchilin et al., 2003). For the delivery of siRNA, liposomes 
modified with R8 have been used, which showed very high blood serum stability as 
well as transfection in Lipofectamine 2000-resistant SK-MES-1 lung tumour cells 
(Zhang et al., 2006). 
1.4.4. Internalisation Mechanisms of CPPs 
The internalisation mechanism of many CPPs remains unclear, possibly due to the use 
of different methods in different laboratories, which are probably not comparable, but is 
thought to involve a wide range of possibilities (see Figure 1).  
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 Figure 1. Mechanisms of CPP Uptake. 
Many internalisation mechanisms for the cellular uptake of cell penetrating peptides 
have been suggested. They include energy-dependent endocytotic pathways as well as 
energy-independent translocation by pore formation of lipid membrane destabilisation. 
The figure is taken from (Trabulo et al., 2010). 
The first contact of the CPPs with the cell membrane is driven by electrostatic 
interactions with proteoglycans and syndecans, which are the major components of the 
extracellular matrix. The clustering of glucosaminoglycans (GAGs) triggers the 
remodelling of the actin network and guanosine triphosphate hydrolase (GTPase) 
activation and impacts the membrane fluidity (Gerbal-Chaloin et al., 2007; Ziegler, 
2008). Primary amphipathic peptides, consisting of a sequentially hydrophobic and 
cationic domain such as MPG (Morris et al., 1997), transportan (Pooga et al., 1998a) 
and Pep-1 (Morris et al., 2001) bind to neutral anionic lipid membranes, probably 
through hydrophobic interactions and reduce the surface tension (Ziegler, 2008). They 
penetrate deep in the hydrophobic core without spanning the bilayer. Primary 
amphipathic peptides often self-associate in the head group region, insert into the 
membrane and translocate directly by e.g. pore formation (Deshayes et al., 2006). 
Transportan and MPG lead to membrane leakage already at submicromolar 
concentrations (Barany-Wallje et al., 2007), whereas Pep-1 crosses the membrane 
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without inducing leakage (Weller et al., 2005). Besides the formation of pores, other 
direct penetration mechanisms, which are most likely for primary amphipathic CPPs, 
are the formation of inverted micelles (Derossi et al., 1996), the carpet-like (Pouny et 
al., 1992) and the membrane-thinning model (Lee et al., 2005). 
Secondary amphipathic peptides, such as penetratin (Derossi et al., 1996), show their 
amphipathic secondary structure after the interaction with lipids as helixes (Futaki et al., 
2001) or β-sheets (Oehlke et al., 1997). Their insertion into the bilayer is not very 
pronounced. At low micromolar CPP concentrations high fractions of anionic lipids 
(> 10 %) are needed for membrane binding, not typical in eukaryotic cells (Ziegler, 
2008). The same was reported for non-amphipathic CPPs such as R9 - direct 
translocation was not seen at low micromolar concentrations. Instead it has been 
reported that penetratin and polyarginines bind to the membrane mainly through 
electrostatic interactions and trigger the cellular uptake of energy-dependent 
endocytosis (Murriel et al., 2006). Endocytosis can be subdivided in phagocytosis (large 
particle uptake) and macropinocytosis (solute uptake). In macropinocytosis the outer 
surface of the plasma membrane folds inwards, forming an external macropinocytic 
structure that is enclosed and internalised: the macropinosome. It is unknown whether 
CPPs induce specific macropinocytotic pathways, but quite likely that they utilise 
multiple pathways in the fluid phase as well as non-specific adsorptive endocytosis. In 
receptor-mediated endocytosis, clathrin- or caveolin-mediated mechanisms are 
involved, which bind the extracellular molecule followed by an invagination of the 
membrane and the formation of phagosomes (Jones, 2007). Depending on the 
experimental conditions, a CPP uses mostly more than one pathway (Letoha et al., 
2003). After cellular uptake, the endosomal escape remains a major limitation, but is 
has been reported that CPPs traffic through the endoplasmic reticulum and Golgi 
network into the cytosol (Fischer et al., 2004) and that NLS motifs can localise the 
cargo to the nucleus (Simeoni et al., 2003). The incorporation of endosomal breakers is 
a possibility to escape the endosome through proton sponge effects (Yamaguchi et al.). 
Another possibility is the use of endosomolytic reagents like chloroquine (Veldhoen et 
al., 2006) or endosomolytic peptides, which acidic residues get protonated at a result of 
endosomal acidification leading to the formation of an α-helix, which hydrophobic side 
interacts and destabilises the endosomal membrane (Lundberg et al., 2007). Using 
photosensitisers, which localise in the endosomal membrane and destabilise the 
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membrane upon photostimulation to release the entrapped molecules has also been done 
(Hogset et al., 2004). 
In summary, even after two decades of CPP applications in vitro and in vivo the 
internalisation mechanism of the CPPs alone or together with their cargo remains 
controversial and a main subject in research areas. 
1.5. Pro-Apoptotic Peptides as Therapeutic Tools 
Therapeutic peptides mimicking or inhibiting protein-protein interactions have become 
a promising new class of drugs, because of potential great target specificity, easy 
development and low-prized production (Raucher et al., 2009; Vlieghe et al.). This is 
especially relevant in tumour therapy where the delivery of therapeutic peptides is 
limited due to rapid degradation and poor tumour cell penetration. As a result D-amino 
acids can be introduced to improve stability or they can be attached to carriers to 
improve cellular uptake, e.g. CPPs. Therapeutic peptides are classified in three main 
groups: signal transduction-inhibiting, cell cycle-arresting and necrosis- or apoptosis-
inducing peptides. 
1.5.1. Peptides for Signal Transduction Inhibition 
Peptides that interfere with the proliferative signal transduction cascade either inhibit 
mitogenic signals or restore the activity of tumour suppressor proteins. For example, 
researchers developed peptide inhibitors of extracellular signal-regulated kinase (ERK), 
which is one of the most studied transduction cascades transmitting extracellular signals 
to the nucleus, resulting in the activation of transcription factors which are essential for 
proliferation and differentiation (Kelemen et al., 2002). Attaching penetratin or Tat to 
the inhibitor facilitated the uptake and inhibited ERK activation in stimulated NIH 3T3 
(mouse embryo fibroblast) cells or nerve growth factor-treated PC12 
(pheochromocytoma) cells followed by the inhibition of the activation of E twenty-six 
(ETS)-like transcription factor 1 (Elk-1).  
The tumour suppressor protein p53, whose gene is very often deleted or mutated in 
cancer cells, is a transcription factor important for cell cycle regulation and apoptotic 
response to DNA damage. A C-terminal peptide of p53 (peptide 46) fused to penetratin 
was able to activate p53-mediated transcription in cell lines expressing wild-type and 
certain mutant p53 proteins, but not in null p53 cell lines (Selivanova et al., 1997). It 
could restore the growth-inhibition and apoptosis-induction function of two often 
mutated p53 proteins, which was due to the binding of the peptide to the core as well as 
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to the C-terminal domain of p53, which rehabilitated the sequence-specific DNA 
binding of the p53 protein (Selivanova et al., 1999). Furthermore, the peptide induced 
cell death in several cancer cell lines, such as MCF-7 cells (overexpression of wild-type 
p53), but not in non-malignant cell lines containing wt p53 (Kim et al., 1999). This 
therapeutic anticancer peptide is a promising agent for the induction of apoptosis in 
cancer cells carrying p53 abnormalities. 
1.5.2. Peptides for Cell Cycle Inhibition 
Peptides inhibiting cell cycle progression modulate cyclin and cyclin-dependent kinase 
(Cdk) activity. Cdks are activated by cyclin binding or by other Cdk-activating kinases 
(CAKs) and phosphorylate target proteins, which control cell-cycle specific events like 
spindle formation or chromosome condensation. Cdks are therefore great targets for 
anticancer drugs. The inhibition of Cdks is either due to phosphorylation of inhibitory 
sites or due to the binding of Cdk inhibitors (CKIs). Gondeau et al. designed a peptide 
derived from cyclin A, which was able to form stable complexes with Cdk2-cyclin A 
and inhibited its kinase activity (Gondeau et al., 2005). When coupled to the Tat 
peptide, it inhibited the proliferation of several tumour cell lines (including MCF-7 
cells) with IC50s between 2 µM and 14.2 µM in 48 h incubations. 
1.5.3. Peptides for Apoptosis Induction: the Bcl-2 Protein Family 
The pro-apoptotic peptides inhibit members of the Bcl-2 protein family, mimic Bcl-2 
family members or modulate caspase activity. Apoptosis is crucial for the body’s 
homeostasis and for the elimination of cells containing damaged DNA. It is often 
dysfunctional in cancer cells resulting in uncontrolled proliferation. Therefore the 
development of pro-apoptotic peptides for the selective induction of apoptosis in cancer 
cells is of great interest (Ellerby et al., 1999).  
One possibility is to target protein kinase B (Akt kinase). Completely phosphorylated, 
membrane anchored, activated Akt inhibits key apoptosis proteins by phosphorylation 
(Cardone et al., 1998) and regulates NF-κB-mediated transcription of other inhibitors of 
apoptosis (IAPs) (Barkett et al., 1999), which leads to cellular apoptosis protection and 
uncontrolled cancer cell growth. Akt-mediated protection against apoptosis can be 
stopped by its interaction with the cell membrane or by inhibiting its substrate 
phosphorylation activity. Indeed, Hiromura et al. (Hiromura et al., 2004) was able to 
deliver an Akt-inhibitor peptide by fusing it to the CPP Tat in human T cells, which 
interacted with it and specifically inhibited its kinase activity. This peptide chimer was 
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able to inhibit cell proliferation and anti-apoptosis activity in vitro as well as tumour 
growth in vivo.  
Furthermore, pro-apoptotic peptides can target the anti-apoptotic B-cell lymphoma 2 
(Bcl-2) family proteins (Lutz, 2000). The family of Bcl-2 proteins consists of pro- and 
anti-apoptotic regulator proteins all sharing the Bcl-2 homology 3 (BH3) domain. Pro-
apoptotic Bcl-2 proteins contain either only the BH3 domain [e.g. Bcl-2-associated 
death promoter (BAD) protein] or several domains [e.g. BH1-BH3 in Bcl-2-associated 
X protein (Bax)] which induce apoptosis by promoting cytochrom c release from the 
mitochondria, followed by the activation of caspases mediating the cell death. In cancer 
cells the anti-apoptotic side of the Bcl-2 proteins is overexpressed. Anti-apoptotic 
proteins such as Bcl-2 or Bcl-xL neutralise pro-apoptotic Bax or BH3-only proteins and 
decrease the cell’s susceptibility to cell death. 
In one study, BH3 peptides derived from the pro-apoptotic Bcl-2 family members were 
conjugated to Antennapedia and introduced into head and neck squamous carcinoma 
cell lines, which overexpress the anti-apoptotic protein Bcl-XL (Li et al., 2007). The 
Antp-BH3 peptides colocalised with the mitochondria and induced viability reduction 
and apoptosis. 
With the goal to restore apoptosis in cancer cells, Valero et al. designed a peptide 
encompassing two central helices of the membrane pore-forming domain of the pro-
apoptotic Bcl-2 protein Bax (Valero et al., 2011). This peptide alone was sufficient to 
insert in the mitochondrial outer membrane resulting the loss of the transmembrane 
potential, membrane disruption and cytochrome c release. Furthermore, the peptide 
itself delivered GFP to the mitochondria, induced caspase-dependent apoptosis and was 
even more effective than the widely used pro-apoptotic KLA peptide (discussed in more 
detail later). When coupled to the CPP octaarginine it efficiently penetrated HeLa cells 
and induced toxicity with a LC50 of 15 µM after 24 h, which could be assigned to 
apoptosis induced by the Bax-derived peptide. Moreover, the R8-Bax [106-134] peptide 
showed anticancer activity in tumour-bearing mice. 
1.5.4. Peptides for Apoptosis Induction: The Pro-Apoptotic KLA Peptide 
A widely used pro-apoptotic peptide is the polycationic KLA peptide with the sequence 
(KLAKLAK)2 (Ellerby et al., 1999). Due to their positive charge, pro-apoptotic KLA 
peptides are attracted by negatively charged membranes e.g. mitochondrial membranes, 
where they distort the lipid matrix. Losing the membrane barrier function, mitochondria 
swell and cells undergo apoptosis. Since the eukaryotic plasma membrane has a low 
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transmembrane potential, these peptides usually remain non-toxic outside the cell, but 
induce apoptosis when transported across the plasma membrane (Lemeshko, 2010). 
When KLA was coupled to hepta-arginine, both isoforms (L- and D-) induced 
permeabilisation of the inner and outer membranes of rat liver mitochondria at 3.6 µM. 
Furthermore, they induced mitochondrial aggregation thereby stopping their metabolic 
activity, which was strongly dependent on the inner membrane potential of the 
mitochondria. Therefore, the higher anti-cancer activity of  R7-KLA and r7-kla (D-
isoform) in comparison to just KLA or kla alone is not only due to a better plasma 
membrane penetration (Law et al., 2006), but also due to the presence of arginine-rich 
CPPs, which increase the direct permeabilisation of mitochondrial membranes in a 
potential dependent mechanism. This finding might be important, taking into account 
that plasma and mitochondrial membrane potentials are usually higher in tumour cells 
than in normal cells (about 60 mV higher in the mitochondria of cancer cells) (Chen, 
1988). Coupling the KLA-peptide to tumour homing devices resulted in the disruption 
of mitochondrial membranes, the growth inhibition of human dermal microvessel 
endothelial cells (DMECs) under angiogenic conditions of proliferation and cord 
formation, but not under angiostatic ones and even induced anti-cancer activity in mice 
(Ellerby et al., 1999). 
In another approach the KLA peptide was delivered using a multimeric RGD-containing 
scaffold, which released KLA by disulfide bridge cleavage after internalisation by 
receptor-mediated endocytosis (Foillard et al., 2009). In a different study, KLA was 
coupled to R8 and induced toxicity (IC50) at 2 µM and 4 µM in human myeloid KG1a 
and HeLa cells (Watkins et al., 2009). Furthermore, researchers reckoned some of the 
cytotoxic effects mediated by r8-kla were due to direct effects on the plasma membrane 
and its increased permeability, since they observed cellular propidium iodide entry after 
10 minutes as well as membrane blebbing. 
To selectively induce apoptosis in malignant cells whilst showing little cytotoxicity in 
normal cells, the cytokine TRAIL (tumour necrosis factor-a related apoptosis inducing 
ligand) has been widely used (Hopkins-Donaldson et al., 2000). TRAIL binds to death 
receptors and induces apoptosis. Unfortunately, many tumour cells are resistant to 
TRAIL-induced apoptosis due to e.g. loss of caspase-8 activity (Hopkins-Donaldson et 
al., 2000) or constitutively active Akt protein kinase (Chen et al., 2001). Therefore, the 
use of KLA is of high importance, since it can be used to overcome TRAIL resistance 
(Barua et al., 2010). KLA was used for the chemosensitisation of two TRAIL-resistant 
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human prostate cancer cell lines to death receptor (DR) agonistic antibodies. KLA alone 
had no effect at low concentrations (1-15 µM), but induced swelling necrosis (oncosis) 
at > 30 µM. A KLA concentration of 15-25 µM was then used to sensitise the cells to 
the apoptotic effects of the DR agonists. Pre-incubation with KLA before treatment with 
DR agonistic antibodies resulted in an increase in caspaser-3 cleavage and cytochrome c 
levels. This shows that KLA can be used to sensitise TRAIL-resistant cells to DR-
mediated apoptosis. 
Another study used three triphenyl phosphonium (TPP) cations to deliver KLA 
(Kolevzon et al., 2011). TPPs accumulate in the mitochondria due to the high negative 
mitochondrial potential (Murphy et al., 2007), but are highly affected by its cargo: no 
mitochondrial localization after conjugation to CPPs (Ross et al., 2004). The delivery of 
3-TPP-KLA induced mitochondria-dependent apoptosis in HeLa cells with an IC50 of 
25 µM after 3 hours incubation. Furthermore, the conjugation of three TPPs to the N- or 
C-terminus did not influence the cytotoxic KLA activity. 
KLA has also been used in the fight of obesity (Kolonin et al., 2004). It was coupled to 
a homing peptide of white fat vasculature and was able to ablate white fat in obese mice 
resulting in the upregulation of lipid turnover and an increased metabolic rate followed 
by the reversal of obesity and metabolic normalisation as well as no detection of 
adverse effects. Since the target of the homing peptide also exists in humans, this study 
is promising for the development of targeted drugs to treat human obesity.  
These examples show, that mitochondrial membrane-disrupting peptides like KLA are 
promising tools for future cancer therapies, since they do not rely on the intrinsic 
expression of pro-apoptotic Bcl-2-like proteins and can be used in a wide range of cell 
types. Since they have proven applicability in vivo (Kolonin et al., 2004), their future 
use as therapeutic peptides is very likely.  
1.6. Objective and Strategy 
Major limitations in the clinical implementation of peptide-based drugs have risen from 
their incapacity to cross biological membranes. Cell penetrating peptides are promising 
tools to improve the intracellular delivery of various cargoes including peptides and 
proteins [as reviewed in (Dietz et al., 2004; Sawant et al., 2009)]. However, for a 
therapeutical application (e.g. cancer treatment with pro-apoptotic peptides) it is still a 
challenge to choose “the” appropriated CPP. 
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Nowadays, only a few comparative studies of CPP internalisation have been performed 
(El-Andaloussi et al., 2007; Fischer et al., 2004; Fotin-Mleczek et al., 2005; Maiolo et 
al., 2005; Sarko et al., 2010; Tunnemann et al., 2008; Wender et al., 2000). 
Nevertheless, differences in numerous variables relating to the experimental procedures 
used by various groups make it hard to compare studies and form any conclusions, 
especially about the mechanism of internalisation. These variables include: different 
sources and purity of CPP, label or cargo used, concentration of CPP, cell-type, density 
and stage of cell cycle, incubation time and final end point or read-out. 
With regard to a clinical application of anti-cancer drugs such as biological active 
peptides, the best CPP suited for that application should be determined in vitro. In this 
study the internalisation of the apoptosis-inducing KLA peptide is supposed to be 
achieved via a non-covalent strategy meaning a simple co-incubation procedure of both 
- CPP and KLA peptide. This approach represents a huge advantage for the future 
therapeutic utilisation: (I) It is much easier and quicker to mix the appropriate CPP with 
the corresponding therapeutic peptide instead of newly synthesising the chosen set; (II) 
It is possible to change the pro-apoptotic peptide quickly in case resistance occurs. 
Furthermore, the likelihood of negative influences of the CPP on the activity of the 
cargo peptide, and vice versa, is hopefully reduced by the non-covalent approach. 
Since there has been no large-scale systematic attempt to determine which CPP 
sequence shows optimal cellular uptake, the internalisation of 22 different CPPs will be 
compared in various commonly used cell types. In a first step, the standard assay 
conditions will be defined allowing direct comparison of the measured cellular uptake, 
toxicity and their subcellular localisation (vesicular or evenly distributed). To measure 
cellular CPP uptake, fluorescein labelled CPPs will be used, which can be measured in 
the lysate using a microplate reader and visualised by confocal microscopy. The toxicity 
of the peptides will be assessed by a MTT assay. The resulting uptake information 
should allow the classification of the CPPs by their internalisation rates and help to 
select promising CPPs for efficient KLA-peptide delivery. 
Besides the search for the most promising CPP, the internalisation mechanism will be 
analysed using different endocytosis modulators (e.g. chlorpromazine or nystatin) or 
depleting energy-dependent processes (4°C). Furthermore, the influence of CPP C-
termini (carboxylated versus carboxyamidated) on the peptide’s uptake, cellular 
localisation and toxicity will be analysed due to the fact that CPPs with different C-
termini have been used in various studies (Weller et al., 2005; Zorko et al., 2005). 
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After this intense comparative exploration, a subset of CPPs showing no toxicity, good 
uptake and cytosolic localisation will be chosen for a successful KLA peptide delivery 
in cancer cell lines, such as breast cancer MCF-7 cells and RAW 264.7 macrophages in 
comparison to fibroblasts (Cos-7). Using the co-incubation strategy, the optimal 
molecular mixing ratio of CPP:KLA will be determined. Thereafter, KLA-delivery will 
be assessed by measuring intracellular Cy5-labelled KLA in cell lysates as well as by 
the detection in live cells with confocal microscopy. Since it has been stated that a 
cysteamide at the C-terminus is required for efficient gene transfection (Simeoni et al., 
2003) as well as for protein delivery (Simeoni et al., 2003; Wells, 2004), the influence 
of carboxylated and carboxyamidated CPP C-termini on the delivery of the KLA 
peptide should be evaluated. Finally the activity of the pro-apoptotic peptide will be 
determined using different routinely used methods such as nucleus condensation 
(microscopy), DNA fragmentation (ELISA) or caspase-3 activity (western blot, specific 
substrate cleavage).  
Altogether, this work should give important background information in the choice of the 
adequate CPP for an anti-apoptotic peptide delivery with regards of future in vivo and/or 
clinical applications. 
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2. EXPERIMENTAL PROCEDURES 
2.1. Peptide Synthesis 
The peptides used were synthesised by the Molecular Libraries and Recognition Group 
(Charité, Berlin) automatically (Syro II, MultiSynTech) using the Fmoc standard 
protocol. Peptides with a C-terminal carboxyl group were generated using TentaGel S 
PHB-aa-Fmoc (Rapp Polymere) and with a C-terminal carboxyamide group using 
TentaGel S Ram resin (Rapp Polymere). For standard synthesis Fmoc-aa-OH were used 
with the following side-chain protections: E-, D-(OtBu); S-, T-, Y-(tBu); K-, W-(Boc); 
N-, Q-, H-(Trt); R-(Pbf) (Novabiochem; Bachem). 5(6)-carboxyfluorescein (CF, Fluka) 
coupling was achieved using 1 equiv. N-hydroxybenzotriazole (HOBt) and 1 equiv. di-
isopropylcarbodiimide (DIC) as activators, as reported in (Fischer et al., 2003). 
Coupling of Cyanine 5 (Cy5) was done with 1 equiv. O-Benzotriazole-1-yl-N,N,N',N'-
tetramethyluronium tetrafluoroborate (TBTU) and 2 equiv. N,N-Diisopropylethylamine 
(DIPEA). The crude peptides were purified to > 95 % by preparative HPLC (Waters) 
and their identity was determined by analytical RP-HPLC (Waters) and MALDI TOF 
mass spectrometry (LaserTec BenchTopII, PerSeptive Biosystems). 
The amino acids are mostly given in the single-letter code, but sometimes in the three 
letter code. 
2.2. Cell Culture 
African green monkey kidney (Cos-7), human embryonal kidney (HEK293), human 
cervix carcinoma (HeLa) and Madin-Derby canine kidney (MDCK) cells were cultured 
in phenol red-free (prf) Dulbecco's Modified Eagle medium (DMEM, Invitrogen) 
supplemented with 10 % fetal bovine serum (FBS, Invitrogen) and 1 % 
penicillin/streptomycin (pen/strep, Biochrom AG). Human breast adenocarcinoma cells 
(MCF-7) were cultured in phenol red-free (prf) RPMI 1640 (Invitrogen), 10 % FBS, 
1 % non-essential amino acids (MEM NEAA, Gibco), 1 mM sodium pyruvate (Gibco), 
and 1 % pen/strep. Mouse leukaemic macrophages (RAW 264.7) were cultured in 
RPMI 1640 (prf), 10 % heat inactivated FBS, 0.05 mM L-glutamine (Gibco) and 1 % 
pen/strep. 
RAEC cells were cultured in Endothelial Basal Medium (EBM, PAA), 10 % FBS, 1 % 
pen/strep. All surfaces, e.g. bottom of culture flasks or well-plates, were coated with 
0.2 % gelatine (Invitrogen).  
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The cells were seeded in the appropriate concentrations (see experimental section 
below) and grown until ~ 80 % confluence at the day of the experiment. Unless 
otherwise indicated, solutions were tempered to 37 °C and all incubations were 
performed at 37 °C, 5 % CO2. 
2.3. Cellular Uptake 
Uptake measurements were performed in 6- or 12-well plates (Falcon, BD Biosciences). 
Cells were rinsed twice with PBS (phosphate buffered saline) and 1 ml 10 µM CF-
labelled CPP solutions in medium without FBS were applied for 30 min at 37°C, 5 % 
CO2. Excess CPPs were carefully removed by two rinses with PBS buffer and cells 
were trypsinated for 10 min at 37°C with 200 µl trypsin [0.05 % trypsin/0.02 % EDTA 
(ethylenediaminetetraacetic acid) (w/v) solution (Biochrom AG)]. Cell solutions were 
transferred to eppendorf tubes. Following two washing steps with PBS and 
centrifugation at 4,000 rpm at 4°C for 10 min, cells were lysed in 500 µl RIPA [50 mM 
Tris, 1 mM EDTA, 150 mM NaCl, 1 % (v/v) NP40, 0.5 % (v/v) deoxycholat, 0.1 % 
(w/v) SDS (sodium dodecyl sulfate), pH 7.5; Complete Mini, EDTA-free (Roche 
Diagnostica GmbH) freshly added] for 1 hour at 4°C. Finally, the samples were 
centrifuged at 8,200 rpm at 4°C for 10 min. 
Signal intensities of CF-CPP were determined using 100 µl lysate in a 96 well plates 
(U96PP, Nunc) with a microplate reader [FLUOstar OPTIMA – BMG Labtech 
(excitation: 485 nm and emission: 520 nm)]. 
Later on, 12-well plates were used with half the volumes for each incubation step. 
The total protein contents were determined by a BCA (bicinchoninic acid) assay where 
5 µl sample and 200 µl BCA-reagent (Reagent A: 1 % (w/v) BCA-Na2, 2 % (w/v) 
Na2CO3, 0.16 % (w/v) Na2-Tatrat, 0.4 % NaOH, 0.95 % (w/v) NaHCO3, pH 11.25 and 
reagent B: 4 % (w/v) CuSO4*5H2O; A:B = 50:1) were mixed and incubated for 30 min 
at 37°C in a 96-well plate (Nunc Maxi Sorb). The absorbance at 620 nm was measured 
and thereafter the concentration was calculated using a bovine serum albumin (BSA, 
Sigma-Aldrich) calibration curve. 
2.4. Endocytosis Inhibitor Test 
All endocytosis inhibitors were purchased from Sigma-Aldrich and used with the 
following concentrations: 30 µM chlorpromazine hydrochloride, 100 µM chloroquine 
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diphosphate salt, 10 µM heparin sodium salt all dissolved in H2O, as well as 100 µM 
nystatin dehydrate and 100 nM wortmannin dissolved in DMSO (dimethyl sulfoxide). 
Cells were pre-incubated with different endocytosis inhibitors for 30 min in medium 
without FBS. Then CPPs were added to a final concentration of 10 µM and incubated 
for 30 min.  
Besides the 37°C CPP incubation, incubations at 4°C were also performed. To minimise 
possible side effects, all solutions were pre-chilled to 4°C. 
Excess CPPs and inhibitors were removed by two rinses with PBS and then the cells 
were trypsinated and lysed with RIPA. As described before, CF-intensities and protein 
concentrations were assessed using microtiter plate reader measurements (FLUOstar 
Optima – BMG Labtech). 
2.5. Cellular Delivery of Peptides 
The basic procedure was done as in described in the chapter “2.3 Cellular Uptake”. 
Cells were seeded, washed and co-incubated with CF-CPPs, cyanine 5 (Cy5)-labelled 
KLA or PRC and CF-labelled CPP-KLA or CPP-PRC peptides for 30 min. Different 
concentrations or mixing ratios are shown in the respective figures (Figure 8 and 
Figure 9). If not otherwise indicated, the CPPs and KLA peptide were directly co-
incubated with the cells without a previous pre-incubation step of both peptides only. 
Finally, the peptide solutions were washed off, the cells were lysed and Cy5-intensities 
were measured in the lysate via a microplate reader (FLUOstar Optima – BMG 
Labtech; excitation 640 nm, emission 680 nm). The CF-CPP uptake was monitored as 
well to ensure consistency. The protein content in the lysate was determined using a 
BCA assay.  
2.6. Confocal Laser Scanning Microscopy 
The cellular localisations of CF-labelled CPPs were detected together with the 
membrane-labelling dye trypan blue with a confocal microscope [inverted IX81 
fluorescence microscope equipped with a Fluoview 1000 scanhead (Olympus) and a 
60× (N.A. 1.35) oil-immersion objective at 25°C]. The green CF fluorescence was 
excited with the 488 nm laser line of an Argon-ion laser, while the red trypan blue 
fluorescence was excited with a 543 nm Helium–Neon laser. The system was run in 
sequential scanning mode, where only one laser was active at a time to avoid spectral 
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overlap. The emission of CF was recorded between 500 nm and 530 nm. For trypan 
blue, the emission was recorded from 570 nm to 670 nm.  
To detect the KLA delivery by CPPs, the KLA peptide was labelled with Cy5. Cells 
were incubated with KLA and CPPs at respective concentrations (Cos-7: 10 µM 
Integrin + 10/20 µM KLA; MCF-7: 1 µM Integrin + 1/2 µM KLA; RAW 264.7: 1 µM 
MPG + 1/2 µM KLA) for 30 min, washed and analysed in complete growth medium. 
HOECHST 33342 (Molecular Probes) was used to stain nuclei. The pictures were then 
obtained using a Zeiss Axiovert 200M fluorescence microscope (Carl Zeiss).  
For nuclear morphology analysis, cells (8×104 cells per dish) were seeded and the next 
day incubated with indicated CPP:KLA complexes. Directly after or after 24 h or 48 h 
the cells were stained with 10 µg/ml HOECHST 33342 (Molecular Probes) for 30 min. 
The nuclear morphology was analysed with a Zeiss Axiovert 200M fluorescence 
microscope (Carl Zeiss). 
All measurements were performed with living, non-fixed cells grown in glass bottom 
dishes (World Precision Instruments). 
2.7. MTT Assay 
A good cellular tolerance is highly important for the use of CPPs as delivery reagents. 
Cell viability was determined using the CCK-8 kit (Fluka) as described by the 
manufacturer. In a few words, to test the cytotoxicity of CPPs 5×105cells were seeded in 
96-well microtiter plates (Falcon) and cultivated over night (37°C, 5 % CO2). Then they 
were incubated with peptides for 2 h in FBS-free medium, washed and further incubated 
with the appropriate medium containing FBS and the MTT dye for 4 h. This 
measurement of cell viability is based on the principle that the WST-8 (water soluble 
tetrazolium salt) dye is reduced in cells by dehydrogenases giving a yellow coloured 
product (formazan), which is soluble in the tissue culture medium. The amount of the 
formazan generated by the activity of dehydrogenases in cells is directly proportional to 
the number of living cells. The absorbance of the formazan product at 570 nm was 
measured using a microplate reader (FLUOstar Optima – BMG Labtech). The results 
were normalised to the control (without peptide) which corresponds to 100 % viability. 
Measurements of the pro-apoptotic KLA peptide activity were performed using the 
MTT test as well. Therefore cells were incubated with CPPs (10 µM for Cos-7, 1 µM 
for MCF-7 and RAW 264.7) and KLA (10 or 20 µM for Cos-7, 1 or 2 µM for MCF-7 
and RAW 264.7) alone or as a mixture. The incubation time was 3 h for Cos-7 cells and 
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1 h for MCF-7 and RAW 264.7 cells. The MTT-test was performed after 3 days for 
Cos-7, MCF-7 cells and after different time points (0 to 3 days) for RAW 264.7 cells. 
The results were normalised to the control (without peptide) which corresponds to 
100 % viability. 
2.8. Western Blot Analysis 
To detect cleaved caspase-3, cells were subjected to western blot analysis. MCF-7 and 
Cos-7 cells were seeded 3.2×104 cells/well in 6 well plates. The next day, MCF-7 cells 
were incubated with 1 µM MPG-CONH2 and 2 µM KLA for 1 h or 3 h. Cos-7 cells 
were incubated with 10 µM MPG-CONH2 or Int-COOH and 20 µM KLA for 3 h in 
FBS-free medium. Thereafter, the cells were washed with PBS and left in FBS-
containing medium. Either directly after incubation or after 3 days, cells were harvested 
and lysed with RIPA buffer (Sigma-Aldrich) containing protease inhibitor cocktail 
tablets (Sigma-Aldrich) for 30 min shaking at 4°C. Cell lysates were centrifuged at 
8,000 rcf for 10 min at 4°C. 50 µg proteins [BCA Protein Assay Reagent, Pierce] were 
separated by SDS-PAGE electrophoresis and transferred to a polyvinylidene fluoride 
(PVDF) membrane (BioRad). Blots were blocked with 5 % non-fat dry milk in PBS 
(Gibco), 0.05 % Tween-20 (ICN Biomedicals Inc.) for 1 h and incubated with cleaved 
caspase-3 rabbit monoclonal antibody (Cell Signaling - 1:1,000) as recommended by 
the manufacturer. The next day membranes were incubated with the secondary anti-
rabbit IgG-peroxidase antibody (Sigma-Aldrich - 1:1,000). Afterwards membranes were 
washed and incubated with the anti-actin-peroxidase antibody (Sigma-Aldrich - 
1:50,000). The blots were detected with an enhanced chemiluminescence western 
blotting substrate (Pierce). 
2.9. Caspase-3 Assay  
Cos-7 cells were seeded (8×103 cells/well), washed and incubated with 10 µM Int-
COOH and 10/20 µM KLA for 3 h. Using the Caspase-3 Fluorescence Assay Kit 
(Cayman), the caspase-3 activation was measured the same day using the specific 
caspase-3 substrate N-Ac-DEVD-N’-MC-R110, which generates a fluorescent substrate 
upon cleavage by active caspase-3. Active caspase-3 included in the kit was used as a 
positive control. For detailed instructions see the kit protocol. To ensure that the KLA 
peptide’s Cy5-label is not the cause of cell death, the KLA peptide without the 
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fluorophore was tested in this assay. The caspase-3 inhibitor (N-Ac-DEVD-CHO) was 
diluted in assay buffer and used as described by the manufacturer.  
In parallel, MCF-7 cells were seeded (8×103 cells/well), washed, co-incubated with 
1 µM MPG-CONH2 and 1/2 µM KLA for 3 h and caspase-3 activity was accessed in the 
same way as described for Cos-7 cells. 
2.10. DNA-Fragmentation Assay 
Using the Cell Death Detection ELISA kit (Roche Diagnostics), the DNA fragmentation 
in MCF-7 lysates after CPP and KLA incubation was detected with antibodies against 
histones and DNA as described by the manufacturer. Briefly, MCF-7 cells were seeded 
(2×104 cells/well) in 24-well plates (Falcon) and incubated the next day with 1 µM 
MPG-CONH2 and 2 µM KLA for 1 h. DNA fragmentation was measured using the 
supernatants of MCF-7 lysates after 1 day, 2 days or 3 days at 405 nm and 490 nm 
(Tecan). The absorbance values (A405-A490) were normalised to those of untreated cells 
to calculate the nucleosomal enrichment factor. 0.5 µM staurosporine (STS, Sigma-
Aldrich) was used as a positive control.  
2.11. Annexin V/Propidium Iodide Flow Cytometric Analysis 
In apoptotic cells phosphatidylserine (PS) is translocated from the cytoplasmic side of 
the cell membrane to the extracellular side, where fluorescein isothiocyanate (FITC)-
labelled annexin V can bind to it with high affinity. Including propidium iodide (PI) in 
the staining procedure ensures a discrimination between dead, necrotic and apoptotic 
cells. MCF-7 cells were seeded (1.6×105 cells/well) in 12-well plates and the next day 
incubated with 1 µM MPG-CONH2 and 2 µM KLA for 1 h. Cells were harvested 
directly after peptide incubation or after 1 day or 2 days, stained using the FITC-
annexin V/Dead Cell Apoptosis Kit V13242 (Invitrogen) and analysed with a 
BDFACSCanto (BD). 0.5 µM STS were included as positive controls. 
2.12. Statistical Analysis 
All values are expressed as mean ± SEM. Multiple comparisons between groups were 
assessed by one-way ANOVA with Newman-Keuls post hoc test. Probability values 
< 0.05 were accepted as statistically significant and the P values were noted as: not 
significant (ns) for P > 0.05 and * for P < 0.05, ** P < 0.001 and *** P < 0.0001. Data 
was analysed using GraphPad Prism (GraphPad Software, San Diego California USA).  
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3. RESULTS 
3.1. Basic Conditions 
22 different CPPs (Table 1, page 29) were selected covering the three main CPP 
families (protein-derived, designed or model CPPs) to evaluate their cellular uptake in 
four most utilised epithelial cell lines (Cos-7, HEK293, HeLa, MDCK). As negative 
control one CPP was synthesised in a scrambled version (pVEC-scrambled). A 
literature screen showed that groups used different concentrations ranging from 1 µM to 
50 µM (Lebleu et al., 2008; Pujals et al., 2008) without getting toxic side effects 
(Duchardt et al., 2007; Tunnemann et al., 2008). By using a concentration of ≥ 10 µM 
Durchardt et al. showed a significant enhancement of cellular uptake. After the 
performance of time dependent assays, a 30 min incubation time proved sufficient and 
that longer incubation times of 45 min or 60 min only increased the CPP uptake little 
(factor 1.4, data not shown). Therefore and keeping toxicity in mind, the analytical 
evaluation of the CPP uptake was started using a CPP concentration of 10 µM and an 
incubation time of 30 min as standard incubation condition unless otherwise stated. 
CPPs are highly positively charged peptides and therefore stick very well to the 
negatively charged plasma membrane on the cellular outside. To avoid these false 
positive uptake signals a trypsinisation step should be carried out before fluorescence 
measurements (flow cytometry or plate reader). For the microscopic evaluation an 
extra-cellular fluorescence quencher should be added to the cells (e.g. trypan blue to 
quench green fluorescence) (Green et al., 1988; Mueller et al., 2008; Richard et al., 
2003). 
Also, the use of living, non-fixed cells during microscopy is highly important, because 
formaldehyde or methanol fixation prior to a microscopic analysis can lead to an 
artificial redistribution of the CPP in the nucleus (Melikov et al., 2005; Richard et al., 
2003). At low CPP-concentration (≤ 10 µM), fixation can lead to broad cytoplasmic and 
nuclear localisation instead of a vesicular distribution in live-cell imaging.  
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Table 1: Peptide Names and Sequences 
Peptide Name Sequence AA pI MW [Da]  Reference 
 Protein-derived 
 CPPs 
SynB1 RGGRLSYSRRRFSTSTGR 18 12.30 2460 (Rousselle et al., 2000) 
Polyomavirus Vp1 APKRKSGVSK 10 11.26 1417 (Saphire et al., 2000) 
Penetratin RQILIWFQNRRMKWKK 16 12.31 2591 (Derossi et al., 1994) 
Tat GRKKRRQRRRPPQ 12 12.70 2078 (Vives et al., 1997) 
Bac1-15 RRIRPRPPLPRPRP 14 12.70 2123 (Sadler et al., 2002) 
NF-kB VQRKRQKLMP 10 12.02 1643 (Ragin et al., 2002) 
SV40 T antigen PKKKRKV 7 11.33 1242 (Lanford et al., 1986) 
HATF3 ERKKRRRE 8 11.55 1517 (Ragin et al., 2002) 
hCT(9-32) LGTYTQDFNKFHTFPQTAIGVGAP 24 6.74 2970 (Trehin et al., 2004) 
Rev TRQARRNRRRRWRERQR 17 12.60 2797 (Futaki et al., 2001) 





Integrin VTVLALGALAGVGVG 15 5.49 2456 (Zhang et al., 1998) 
 Designed CPPs 
 
DPV6 GRPRESGKKRKRKRLKP 17 12.19 1656 (De Coupade et al., 2005) 
S413PV ALWKTLLKKVLKAPKKKRKV 20 11.51 2437 (Mano et al., 2005) 
Transportan GWTLNSAGYLLGKINLKALAALAKKL 27 10.18 2736 (Pooga et al., 1998a) 
Pep-1 KETWWETWWTEWSQPKKKRKV 21 9.82 3201 (Morris et al., 2001) 
MPG GALFLGWLGAAGSTMGAWSQPKKKRKV 27 11.33 2237 (Morris et al., 1997) 
 Model CPPs MAP KLALKLALKALKAALKLA 18 10.60 3208 (Oehlke et al., 1998) 
poly-P VRLPPPVLRPPPVLRPPP 18 12.30 2357 (Fernandez-Carneado et al., 2004) 
R7 RRRRRRR 7 12.78 1471 (Wender et al., 2000) 
R9 RRRRRRRRR 9 12.90 1783 (Wender et al., 2000) 
 Others pVEC-scrambled IAARIKLRSRQHIKLRHL 18 12.48 2569 (Elmquist et al., 2003) 
Footnote: CPPs were synthesised as amide (-CONH2) or as carboxyl (-COOH). Furthermore, CPPs were N-terminally labelled with (5/6) 
carboxyfluorescein (CF-) for uptake and microscopic analyses. The theoretical isoelectric point (pI) was calculated with the ProtParam tool 
(http://web.expasy.org/protparam/). 
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3.2. Evaluation of Cellular Uptake: 22 CPPs in 4 Cell Lines 
3.2.1. Viability Test of the 22 CPPs 
First of all, the potential cellular toxicity of the 22 different CPPs was examined, since 
this is crucial to their use as effective delivery vehicles. To provide information about 
acute toxicity, cells were incubated for two hours with 22 CF-labelled CPPs at 
concentrations of 1 µM - 50 µM (Annex - Table 5). Afterwards, the cells were washed, 
incubated with the vital MTT dye and the formazan formation was detected at 570 nm. 
Most of the CPPs showed no cytotoxicity even at high concentrations (100 ± 20 % 
viability). S413PV was the only peptide that lowered the viability substantially at 10 µM 
(HeLa 64 ± 24 % viability and MDCK 33 ± 16 % viability) and at ≥ 25 µM for all cells. 
Also, at 25 µM transportan and MAP decreased the cell viability. For example, 
transportan caused strong reductions at 25 µM in Cos-7, HeLa and MDCK cells (20 – 
0 %) but had a lower effect on HEK293 cells (~ 50 %). The decreasing cell viabilities 
induced by these three CPPs are not surprising due to the fact that they are postulated to 
penetrate the cell by pore formation (Matsuzaki, 1996). However, to assess cytotoxic 
effects of the CPPs in the MTT assay, the incubation time was prolonged to 2 h. Most 
CPPs seem to have no influence on cell viability even under these extreme conditions.  
Altogether, these results substantiate the used standard conditions (10 µM CPP for 
30 min) to analyse the internalisation properties of the 22 CPPs. 
3.2.2. Comparing Cellular CPP Uptake and Distribution 
The cellular uptake rates of the 22 CPPs were quantified in Cos-7, HEK293, HeLa and 
MDCK cells by fluorescence measurements using a microplate reader (Figure 2, 
page 31). Although all 22 CPPs are known from the literature and are supposed to have 
cell penetrating properties, they do not show the same degree of cellular uptake. 
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Figure 2. CPP Uptake in Cos-7, HEK293, HeLa and MDCK Cells. 
Cells, which were 80 % confluent, were washed and incubated with 10 µM CF-CPPs 
for 30 min at 37°C. After further washing and trypsinisation (10 min at 37°C) to avoid 
the measurement of membrane bound, but not internalised CPPs, the cells were lysed. 
The CPP amount in the lysate was quantified via the peptide’s CF-label (excitation: 
485 nm and emission: 520 nm) and normalised to the total protein content using a BCA 
assay (absorbance measurement at 620 nm). Classification corresponds to low 
(< 500 SI/mg protein), medium (500 – 1,000 SI/mg protein) and high (> 1,000 SI/mg 
protein) internalisation. The data represents the mean ± S.E.M. (n≥3). 
Figure 2 shows that the degree of cellular penetration varies highly. First of all, the used 
negative control pVEC-scrambled did not show any internalisation compared to 
untreated cells. Altogether, the CPPs can be classified in three groups showing low 
(< 500 SI/mg protein), medium (500 – 1,000 SI/mg protein) and high (> 1,000 SI/mg 
protein) cellular uptake. Surprisingly there are a large number of 14 CPPs in the first 
group with low or nearly no cellular penetration in the tested cell lines (for instance 
hCT(9-32), Tat or Pep-1). The second group with medium cellular uptake in most cell 
lines comprises four CPPs including Rev, S413PV, R9 and integrin. CPPs with high 
uptake rates in most cells are the four commonly used CPPs MPG, penetratin, MAP and 
transportan. The overall lower cellular uptake of Tat compared to penetratin and the 
polyarginines was confirmed (Fischer et al., 2004; Wender et al., 2000) as well as the 
efficiency of R9 compared to R7 for HeLa and HEK293 cells, which is in accordance 
with Tunnemann et al. (Tunnemann et al., 2008). 
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Interestingly, integrin prefers HEK293 cells (3-fold higher SI/mg protein compared to 
the other cells), penetratin HeLa cells (3-fold higher uptake) and transportan MDCK 
cells (2-fold higher uptake). Amongst the 22 CPPs used, none internalises in Cos-7 cells 
better than in the other cell lines.  
To investigate the subcellular localisation of the 22 CPPs, microscopic experiments 
were performed using representing candidates from the three determined uptake-groups: 
polyomavirus Vp1 as an example of a CPP with low cellular uptake, integrin and R9 as 
examples of medium uptake and MAP, MPG, penetratin and transportan as examples of 
high uptake rates (Figure 2). Tat was included, because it is widely used in the scientific 
community. 
Figure 3 (page 33) summarises the distribution of an exemplarily subset of eight CPPs 
within the four cell lines. In the control picture (without CPPs) no self-fluorescence of 
the cells was measured (Figure 3, 1st panel). Additionally, to avoid misinterpretation due 
to extracellular CPP fluorescence bound to cell membranes or working materials, trypan 
blue solution was added during each CLSM (confocal laser scanning microscopy) 
measurement (only shown in the last panel). Trypan blue is unable to translocate intact 
cell membranes, which makes it a selective quencher for extracellular bound 
fluorophores (Foerg et al., 2007; Hed et al., 1987). 
First of all, by subjectively comparing the fluorescence pictures, the results obtained by 
the microplate reader could clearly be reproduced (Figure 2). CPPs showing low 
(polyomavirus Vp1) and high (penetratin, transportan, and MAP) cellular uptake also 
show low or bright green fluorescent signals in the CLSM pictures. 
Tat mainly shows a vesicular distribution in all cells, and furthermore, a diffuse 
cytoplasmic and additionally nucleic localisation in the case of HeLa and MDCK cells 
(Figure 3, 3rd panel). Due to the additional cytoplasmic and nucleic distribution in HeLa 
and MDCK cells, the quantity of internalised CPPs seems to be higher than in the other 
two cell lines, which does not correspond to the approximately equal distribution 
measured by the microplate reader (Figure 2). At this juncture, it can only be postulated 
that nuclear located CPP could not be exactly measured in cell lysates. 
Penetratin (Figure 3, 4th panel) displays a punctuated dispersion within the three cells, as 
is also observed for the smac-penetratin construct used in HeLa cells (Fotin-Mleczek et 
al., 2005). A similar distribution of R9 was observed in Cos-7, HEK293 and HeLa cells, 
with a pronounced cytoplasmic and nucleic distribution found most strongly in MDCK 
cells (Figure 3, 5th panel). 
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Figure 3: Cellular Distribution of Eight Example CPPs in Cos-7, HEK293, HeLa 
and MDCK Cells.  
As control, the four cell lines without peptide incubations are shown (no CF-staining at 
488 nm) with the corresponding phase contrast images. The four different cell types are 
treated with 10 µM of the CF-labelled CPPs for 30 min. For each condition CF-
fluorescence (488 nm) and phase contrast images are shown. For transportan (last row) 
the vital trypan blue staining (543 nm) is merged with the CF-images. The white bars 
represent 10 µm. 
The fluorescence of MAP (Figure 3, 6th panel) and of MPG (Figure 3, 7th panel) in the 
CSLM pictures appears evenly distributed throughout the cytosol and nucleus, 
accompanied by a punctuated pattern, suggesting that non-endocytotic as well as 
endocytotic modes of uptake are involved.  
Integrin seems to be mostly located close to the cell membrane, especially in Cos-7 and 
HeLa cells, which is in agreement with Zhang et al. (Zhang et al., 1998) (Figure 3, 
8th panel). Transportan plays a special role in the cellular uptake. Using the microplate 
3. RESULTS  34 
 
reader, extremely high incorporations were recorded. Images of confocal microscopy 
show not only cytoplasmic vesicles, but also intense cell damages (Figure 3, 2nd shot of 
transportan). 20-30 % of the cells reveal a huge intracellular accumulation of 
transportan correlating with the trypan blue staining and independent of the cell types. 
This lytic characteristic of transportan was also clearly demonstrated in the viability test 
showing a high cytotoxic effect with a concentration up to 25 µM (Annex - Table 5). 
The similar phenomenon could be observed in 5 % of the HeLa cells incubated with 
MAP (data not shown). 
3.2.3. Influence of Endocytosis Modulators on the Cellular Uptake 
To gain more insights into the mechanism(s) by which CPPs are taken up by cells, eight 
CPPs from Figure 3 as well as four others were selected and tested with chemical 
inhibitors to block specific endocytotic pathways, compete with membrane associated 
HSPGs or inhibit endosome acidification or fusion. Cells were pre-treated with the 
chemicals (Table 2) for 30 min before the main incubation (10 µM CPPs + inhibitors) 
and analysed using a microplate reader.  
Table 2: Endocytosis Modulation 
 Treatment Concentration Consequence 
      37°C - Standard condition 
 4°C - Inhibition of energy-dependent processes 
 Chlorpromazine 30 µM Inhibition of clathrin-dependent endocytosis 
 Chloroquine 100 µM Inhibition of endosome acidification 
 Nystatin 100 µM Disrupt caveolar structure and function 
 Heparin 10 µM Competitor of cell membrane-associated HSPGs 
 Wortmannin 100 nM Inhibition of endosome fusion 
Footnote: The concentrations given in the table are the concentrations used in this study. 
Additionally, a brief description of the proposed exerted effect on endocytosis is given 
for each substance. HSPGs: heparin sulfate proteoglycans. 
Besides the standard conditions at 37°C, energy-dependant pathways were tested by 
measuring CPP uptakes at 4°C. Chlorpromazine was used as a clathrin-dependent 
endocytosis inhibitor and nystatin disrupts caveolar structures and functions. 
Chloroquine was utilised inhibiting the acidification of endosomes, and the fungal 
metabolite wortmannin inhibiting fluid phase uptake and the homotypic fusion of early 
endosomes (Jones, 2007). Furthermore, heparin was used as a competitor of cell 
membrane-associated heparin sulfate proteoglycans (HSPGs), which are known to 
mediate the first interaction with CPPs (Ziegler, 2008).  
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Comparing the four cell lines, the most positive effects were seen with heparin (58 %), 
chloroquine (58 %) and at 4 °C (48 %), suggesting an energy- and clathrin-dependent 
pathway for uptake. By looking at the overall results, the most frequent negative effects 
were observed in HEK293 cells, at temperatures of 4 °C (58 %), with nystatin (50 %) 
and wortmannin (58 %) reflecting an energy- and caveolin-dependent pathway. A more 
equal distribution of positive and negative effects was found for HeLa and MDCK cells. 
Altogether, most of the inhibitors used seem to have weak consequences for the cellular 
uptake: 44 % of the conditions have no effect on Cos-7, 50 % on HEK293, 63 % on 
HeLa and 70 % on MDCK cells. These results were confirmed by confocal microscopic 
analysis (Mueller et al., 2008).  
Altogether, adding different endocytosis modulators mostly did not change the cellular 
uptake as well as the subcellular CPP localisation. 
3.3. Evaluation of CPP Uptake in Other Cell Types 
Having completed the analytical evaluation of the 22 CPPs in four cell lines, three 
additional cell types were selected to confirm the results. The adenocarcinoma cell line 
MCF-7 and the leukaemic macrophagic cell line RAW 264.7 were chosen as examples 
of cancerous cell lines as well as the aortic endothelial cells RAEC [kindly provided by 
Dr. Martina Seifert (IMI, Charité)], as an example for primary cells. The same 22 CPPs 
were analysed quantitatively by microplate reader measurements and qualitatively by 
confocal microscopy as described in the previous chapter. 
The cytotoxicity of CPPs is very important for their use as delivery vehicles. Therefore 
all three cell types were incubated with the peptides in different concentrations (1 µM – 
50 µM) for two hours and the cellular viability was determined using the MTT assay. 
Fortunately, most of the CPPs did not influence the cellular viability even at a high 
concentration of 25 µM in MCF-7, RAW 264.7 and RAEC cells. Here again, especially 
S413PV revealed toxic properties at 10 µM or 25 µM (Annex - Table 7). Since much 
shorter incubation times in the uptake experiments were used (30 min compared to 2 h 
applied here) a 10 µM peptide solution seems to be non-toxic. 
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Figure 4. Comparison of CPP Uptake in MCF-7, RAW 264.7 and RAEC Cells. 
80 % confluent cells were incubated with 10 µM CF-CPPs for 30 min at 37°C. The cells 
were then washed and treated with trypsin (10 min at 37°C) to avoid the measurement 
of membrane bound, but not internalised CPPs. After cell lysis, the CPP amount was 
quantified via the peptide’s CF-label (excitation: 485 nm and emission: 520 nm) and 
normalised to the total cellular protein content using a BCA assay (absorbance 
measurement at 620 nm). The data represents the mean ± S.E.M. (n≥3). 
As in the previously analysed cell lines (Figure 2), the 22 CPPs show very different 
uptake properties (Figure 4) and can be classified in the same three main internalisation 
groups although with some exceptions. The CPP group of high uptake rates 
(> 1,000 SI/mg protein for MPG, penetratin, MAP, transportan) also shows high 
penetration in the MCF-7, RAW264.7 and RAEC cells. Also, CPPs that internalised 
poorly in the previous four cell lines, (< 500 SI/mg protein), show mostly low uptake 
rates here as well (e.g. polyomavirus Vp1, hCT(9-32) and Tat). Only the two CPPs 
Pep-1 and pVEC switch their classification group showing here a higher cellular 
penetration in the new three analysed cell types (see arrows in Figure 4). 
Interestingly, some CPPs such as MPG, S413PV, MAP, R9, Rev and pVEC penetrated 
MCF-7 cells better compared to the other tested cells. Transportan penetrates primary 
aortic cells about 8-fold better than the other two cell lines (27,389 ± 6,873 SI/mg 
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protein versus 3,374 ± 433 SI/mg protein in MCF-7 and 3,520 ± 664 SI/mg protein in 
RAW 264.7) and even better than Cos-7, HEK293, HeLa and MDCK cells. 
The cellular location of the CPPs was analysed by confocal microscopy using a subset 
of six CPPs. This time polyomavirus Vp1 and transportan were not included, because 
Vp1 shows no significant uptake and transportan seems to be cytotoxic as shown in 
Figure 3 (upper panel). 
Figure 5. Cellular Distribution of Six CPPs in MCF-7, RAW 264.7 and RAEC 
Cells. 
MCF-7, RAW 264.7 and RAEC cells were incubated with 10 µM CPPs for 30 min, 
washed and analysed by confocal microscopy. Trypan blue was added to quench 
extracellular fluorescence (data not shown). For each condition the phase contrast image 
as well as the CF-CPP staining (488 nm) is shown. The white bars represent 10 µm. 
First of all, the control pictures (Figure 5, 1st panel) show no auto-fluorescence of the 
living, non-fixed cells and furthermore the cells incubated with the CPPs seem to be 
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healthy in every condition tested. The CLSM pictures confirmed the measurements 
done with the microplate reader. Strong uptake values as for penetratin in RAEC cells 
resulted in strong fluorescent signals. The only discrepancy was observed with integrin 
showing an internalisation in MCF-7 cells, but obviously no intracellular fluorescence 
by microscopic detection. 
Altogether, the distribution of the CPPs in the three cell types exhibits a punctuated 
pattern throughout the cytoplasm, which suggests an entrapment of the peptides in 
endosomal vesicles. In some cases (R9 in MCF-7 and S413PV in RAW264.7) a nuclear 
and cytoplasmic distribution of the CPPs was observed. However, the microscopically 
visualised results correspond mainly to the fluorescence measurements by microplate 
reader as previously shown for Cos-7, HEK293, HeLa and MDCK cells (Figure 3). 
3.4. Influence of the CPPs C-Terminus on the Cellular Uptake 
Different studies have been using CPPs with different C-termini (Weller et al., 2005; 
Zorko et al., 2005) and it has been stated that a cysteamide at the C-terminus is required 
for efficient transfection (Simeoni et al., 2003). There has never been a systematic 
evaluation of the influence of the C-terminus on CPP uptake and intracellular 
localisation. Based on the analytical evaluation of 22 CPPs in seven cell type, six CPPs 
were selected (penetratin, Tat, integrin, S413PV, MPG and R9) and synthesised with a 
carboxyamidated (-CONH2) or carboxylated (-COOH) C-terminus to analyse its 
influence on the cellular internalisation and its intracellular distribution. Tat was chosen 
as an example of a CPP with low uptake and also because it is often used in the CPP 
community, S413PV, R9, penetratin and integrin as examples of medium cellular uptake 
and MPG as a CPP with high internalisation properties (according to the classification 
in Figure 2 and Figure 4) (Mueller et al., 2008; Mueller et al., 2011). These CPPs were 
analysed in comparison to each other in the seven cell types used before (chapters 3.2 
and 3.3). 
First of all, the potential cytotoxic effects of the carboxyamidated CPPs were 
determined using the MTT-viability assay (Annex - Table 8). Interestingly, 
carboxyamidated CPPs appear more toxic than carboxylated CPPs. The most toxic 
effects are seen in HeLa cells, beginning at 25 µM (penetratin, Tat, S413PV, R9 and 
MPG). Again S413PV - here in the carboxyamidated version - shows the highest toxicity 
in all cell lines (at 25 µM but sometimes also at 10 µM). Interestingly, integrin reveals 
the lowest influence on cell viability. 
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With the exception of S413PV, no toxicity was observed for carboxyamidated CPPs in 
primary RAEC cells, which is in contrast to carboxylated CPPs, where the most viablity 
reductions were seen in this cell line. 
Figure 6. Cellular Uptake of CPPs with Carboxylated or Carboxyamidated 
C-Terminus. 
Cos-7, HEK293, HeLa, MDCK, MCF-7, RAW 264.7 and RAEC cells were incubated 
for 30 min with the six selected CF-CPPs having either a carboxylated or 
carboxyamidated C-terminus. Then the cells were washed, trypsinised, lysed and 
analysed by microplate reader. The data shown are the mean ± SEM (n=3). 
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All together carboxyamidated CPPs are more toxic to the seven tested cell types than 
carboxylated CPPs, but surprisingly less cytotoxic to the primary RAEC cells than 
carboxylated CPPs. 
Having found that 30 min incubations of 10 µM peptide solutions had no cytotoxic 
effect on most cell types independent of the CPPs’ C-termini, their cellular uptake was 
evaluated and compared to the one of carboxylated CPPs. In analogue to previous 
experiments, cells were incubated with the CF-labelled CPPs and their internalisation 
was quantified by fluorescence measurements in the lysate using a microplate reader.  
The uptake measurements shown in Figure 6 clearly revealed a strong influence of the 
CPP C-terminal character on CPP cellular uptake. The internalisation of the 
carboxyamidated form of penetratin, R9 and integrin is extremely improved in most cell 
types compared to the carboxylated form, e.g. CF-Pen-COOH is internalised with 
311 ± 22 SI/mg protein whereas CF-Pen-CONH2 penetrates at 7,811 ± 1,591 SI/mg 
protein in MDCK cells. In contrast, the uptake of Tat and S413PV is nearly not 
influenced when changing the C-terminus in all analysed cells. Interestingly, the MPG 
uptake rises in most cell lines when carboxyamidated MPG is used (3-fold to 20-fold), 
but shows no significant difference in MCF-7 cells and the primary RAEC cells (e.g. 
6,944 ± 1,831 SI/mg protein for CF-MPG-COOH versus 4,674 ± 1,344 SI/mg protein 
for CF-MPG-CONH2 in RAEC cells). With the exception of RAEC cells, 
CF-MPG-CONH2 is the CPP showing the highest uptake (from 7,008 ± 1,043 SI/mg 
protein in HEK293 to 14,882 ± 4,351 SI/mg protein in MCF-7) when compared to other 
CPPs in that cell type. 
In summary, regarding the seven analysed cell types, the C-terminus change from a 
carboxylate to a carboxyamide enhances the cellular CPP uptake in about 59 % of the 
cases. 
Here again, as mentioned before, the cells were incubated with CF-labelled CPPs and 
analysed by confocal microscopy to determine if the different C-termini might have an 
influence on the CPP’s sub-cellular distribution. Before picture acquisition, the cells 
were incubated with trypan blue as vital dye and as a quencher of extracellular bound 
CF-CPPs. As exemplified in Figure 7, the cellular internalisation of penetratin, S413PV 
and MPG (green fluorescence) in the seven cell lines as a merged picture with the 
trypan blue staining (red fluorescence) is shown as well as the bright field images. The 
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Figure 7. Cellular Distribution of Carboxylated or Carboxyamidated CPPs in Cos-7, HEK293, HeLa, MDCK, MCF-7, RAW 264.7 and 
RAEC Cells.  
Cells were treated with 10 µM of the CF-labelled CPPs for 30 min. For each condition, the overlay of CF-staining (green fluorescence) and trypan 
blue stain (red fluorescence) as well as the phase contrast images are shown. The uptake values measured by microplate reader are given in the left 
lower corner. The white bars represent 10 µM. 
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First of all, the control pictures (Figure 7, 1st panel) show no intrinsic fluorescence in 
the green CF channel. Furthermore, intact cell membranes indicated by the trypan blue 
staining (red fluorescence) correspond to no toxicity of the used CPPs under the applied 
conditions (10 µM, 30 min incubation). Subjectively looking at the images of the 
different cell types, most of them confirmed the measurements done with the microplate 
reader, e.g. CF-Pen-CONH2 in HeLa and CF-MPG-COOH in MDCK cells clearly show 
a stronger fluorescence signal.  
It was not possible to identify a change in the subcellular localisation of the CPPs when 
altering the C-termini for most cell lines - they showed a punctuated pattern throughout 
the cytoplasm, which probably resulted from uptake via endocytosis (Jones, 2008). 
However, MCF-7 cells exhibit a different distribution for carboxylated and 
carboxyamidated penetratin, S413PV and MPG. The carboxyamidated peptides were 
localised not only in the vesicles, probably the endosomes, as seen for their 
carboxylated forms, but also diffused in the cytoplasm as well as in the nucleus. The 
same can be observed for Tat and R9 in RAW 264.7 cells (data not shown) and for 
S413PV in MDCK cells. Only RAEC cells show no altered subcellular distribution after 
a CPP C-terminal change.  
In summary, the conformation of the C-terminus has an influence on (I) the cellular 
CPP uptake (carboxyamidated CPPs > carboxylated CPPs) and in a few cases on (II) the 
CPP’s cellular localisation depending on the CPP and cell line. 
3.5. Cellular Delivery of the Pro-Apoptotic KLA Peptide 
The main purpose of CPPs is their use as delivery vehicles for e.g. biological active 
peptides. To prove their therapeutic applicability by a simple co-incubation with the 
CPPs (non-covalent strategy) into the mammalian breast cancer MCF-7 cells and the 
leukaemic macrophages RAW264.7 compared to the fibroblastic Cos-7, the pro-
apoptotic peptide KLA (Table 3, page 43) (Ellerby et al., 1999) was chosen to be 
delivered into cells keeping a potential application in cancer therapy in mind. 
Additionally, another peptide sequence was used (PRC) to analyse the influence of 
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Table 3: Cargo Peptides 
 Name Sequence Reference 
 KLA KLAKLAKKLAKLAK (Raucher et al., 2009) 
 PRC ANSRWQTSII (Vouilleme et al., 2010) 
Footnote: Peptides were synthesised with N-terminal Cy5-labels for uptake and 
microscopic analyses. 
3.5.1. Optimal Mixing Ratio for the Non-Covalent Delivery of the KLA 
Peptide 
To ensure the best cellular delivery of the KLA peptide, the optimal mixing ratio was 
determined using MPG-CONH2:KLA and Int-CONH2:KLA in Cos-7 cells (both CPPs 
show high internalisations in Figure 6). The cells were co-incubated with Cy5-labelled 
KLA and CF-labelled CPP-CONH2 in different molar ratios (20:1 to 1:2 for CPP:KLA) 
as well as with KLA and CPP alone (Figure 8A). Interestingly, the internalisation was 
dramatically reduced using ratios of 10:1 or 20:1 (CPP:KLA) which are typical ratios 
for CPP:oligonucleotide mixtures (Said Hassane et al., 2009). Furthermore, a 30 min 
pre-incubation of the CPP:KLA mixture before adding to the cells did not increase the 
KLA uptake (Figure 8A, page 44). 
In detail, an increased cellular uptake of the KLA-peptide was observed when incubated 
with the appropriated same amount of CPP compared to the incubation without one. For 
example, incubating Cos-7 cells with KLA together with MPG-CONH2 or Int-CONH2 
roughly doubled or tripled the amount of uptake [e.g. 390 ± 95 Cy5-SI/mg protein for 
KLA alone versus 1,106 ± 230 Cy5-SI/mg protein for Int-NH2:KLA (1:2)]. To check 
the transportation capacity of a CPP with low cellular uptake, the Tat peptide was 
chosen and applied using the co-incubation strategy. The results shown in Figure 8A 
clearly demonstrate that co-incubating Tat with KLA did not improve the 
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Figure 8. Mixing Ratios of the KLA (A) or PRC (B) Peptide and CPPs. 
Mixing ratios of the (A) KLA or (B) PRC peptide and CPPs: Cos-7 cells were incubated with 10 µM CPP and different concentrations of the KLA 
or PRC peptide for 30 min. For all conditions, the peptides were co-incubated; only in (A) MPG-CONH2:KLA solutions were pre-incubated for 
30 min. The Cy5-KLA/PRC uptake was measured and normalised to the total protein concentration (Cy5-SI/mg protein). The CF-CPP uptake was 
also monitored to ensure consistency (data not shown). The maximal uptake was reached using CPP:KLA mixture ratios of 1:1 and 1:2. n.d. means 
‘not determined’. Data shown are the mean ± SEM (n=3). 
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The same mixing ratios resulted in high uptake amounts when a different arbitrary 
chosen peptide was used (PRC, Table 3, Figure 8B). Therefore it is likely that this 
phenomenon was not dependent on the KLA sequence as cargo (positively charged, 
helix conformation) (Ellerby et al., 1999). Even though the overall uptake amounts were 
much smaller for PRC than for KLA, its internalisation was doubled or tripled when co-
incubated with MPG-CONH2 or Int-CONH2 at a ratios of 1:1 or 1:2 compared to the 
internalisation without a CPP as vehicle [104 ± 26 Cy5-SI/mg protein for Cy5-PRC 
alone versus 310 ± 69 Cy5-SI/mg protein for MPG-CONH2:Cy5-KLA (1:2)]. Here as 
well, the internalisation was rather dependent on the used CPP as well as on its C-
terminal conformation. 
These results suggest that mixing ratios of 1:1 and/or 1:2 (CPP:peptide) are the best 
choices for the delivery of a peptide co-incubated with a CPP. However to find the best 
CPP for peptide delivery into a certain cell type using the simple co-incubation strategy 
seems to be rather difficult. It can be believed that a high CPP uptake and a 
carboxyamidated C-terminus are advantageous for a successful peptide delivery – 
however, this should always be tested. 
For all following experiments the ratios CPP:KLA (1:1) and (1:2) were chosen to 
evaluate the uptake and induce pro-apoptotic effects of the transduced KLA peptide. 
3.5.2. Cellular Delivery of the KLA Peptide 
Having found the optimal mixing ratios (1:1 or 1:2), Cos-7, MCF-7 and RAW 264.7 
cells were incubated with KLA together with MPG, integrin or penetratin. Here as well 
the influence of the C-terminus was evaluated, since it has been stated, that a C-terminal 
cysteamide is important for plasmid and cysteamine for protein delivery (Simeoni et al., 
2003; Wells, 2004). To evaluate the influence of the CPP C-terminus on peptide 
delivery, it was tested in both versions (carboxylated versus carboxyamidated) 
(Figure 9). 
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 Figure 9. Cellular Delivery and Distribution of the Pro-Apoptotic KLA Peptide 
Co-Incubated with a CPP. 
(A) KLA delivery by CPPs in Cos-7, MCF-7 and RAW 264.7 cells: Cos-7, MCF-7 and 
Raw 264.7 cells were incubated with CPPs and KLA as described before. “1×” means 
1 µM or 10 µM and “2×” means 2 µM or 20 µM peptide concentration depending on 
the cell lines. The delivery of the KLA peptide was successfully enhanced when co-
incubating it with a CPP in all cell lines. Notice the strong enhancement with Int-COOH 
in Cos-7 and MPG-CONH2 in RAW 264.7 cells. Data shown are the mean ± SEM 
(n=3).         
(B) Cellular distribution of the KLA peptide: Combinations of CF-CPP and Cy5-KLA 
with the symbol # in Figure 9A were analysed under the microscope. Trypan blue was 
added to ensure cell viability, but omitted when KLA was present to avoid spectral 
overlaps. Nuclei were stained with HOECHST 33342. CF-CPPs are visualised in green, 
trypan blue and Cy5-KLA in red. The scale bars represent 10 µm. 
The KLA-delivery in Cos-7 cells is mainly possible with penetratin and integrin. 
However, the internalisation depends on the C-terminus of the CPP, especially in the 
case of integrin. A 5- to 6-fold increase was observed in the KLA uptake with Int-
COOH compared to Int-CONH2 at both ratios (5,085 ± 803 Cy5-SI/mg protein versus 
987 ± 197 Cy5-SI/mg protein for ratio 1:1 and 5,737 ± 705 Cy5-SI/mg protein versus 
1,106 ± 230 Cy5-SI/mg protein for ratio 1:2). 
When applying the same conditions of KLA delivery (10 µM CPP with 1:1 or 1:2 
ratios) in MCF-7 and RAW 264.7 cells, they rapidly detached making the analysis of 
the results difficult. For that reason, these assays were performed using a 10-fold diluted 
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concentrate (1 µM CPP with ratio 1:1 or 1:2). As observed for the Cos-7 cells, an 
enhancement of the KLA internalisation was seen in both cell lines depending on the 
CPP C-terminus, even if the signal was weaker due to lower peptide concentrations. The 
best results were seen with MPG-COOH:KLA (1:2) (423 ± 61 Cy5-SI/mg protein; 3-
fold increase compared to KLA alone) for MCF-7 and MPG-CONH2:KLA (1:2) 
(73 ± 67 Cy5-SI/mg protein 2.5-fold increase compared to KLA alone) for RAW 264.7 
cells. 
Using confocal microscopy the results found by microtiter plate reader measurements 
were confirmed: high uptake corresponded to high fluorescence signals in the analysed 
cells (Figure 9B). For example, the vast difference in transportation capability of both 
forms of integrin was confirmed for Cos-7 cells (Int-COOH:KLA >> Int-CONH2:KLA). 
The higher delivery by Int-CONH2 at a ratio of 1:2 compared to 1:1 in MCF-7 cells as 
well as MPG-CONH2 1:2 in relation to 1:1 in RAW 264.7 cells were also validated. 
Looking at the pictures in greater detail, a huge accumulation of CF-Int-COOH:Cy5-
KLA around the nucleus of Cos-7 cells appeared (merged distribution in orange, 
Figure 9B). Also a strong cellular accumulation of CF-Int-CONH2:Cy5-KLA (1:2) in 
MCF-7 and CF-CPP:Cy5-KLA (1:2) in RAW 264.7 cells were seen, which correspond 
to the values measured in the uptake tests - even at a low concentration (1 µM CPP). 
Interestingly, the cellular distribution seemed to be mainly cytosolic, hinting towards a 
potential entrapment in endosomal vesicles. Since there was also a diffuse signal 
detectable surrounding the vesicles, it is also assumable that KLA is able to escape the 
endosomal entrapment. 
In summary, the KLA peptide was successfully delivered in adenocarcinoma cells 
(MCF-7), leukaemic macrophages (RAW 264.7) and fibroblasts (Cos-7) using the non-
covalent co-incubation approach. In order to obtain high delivery rates, different cell 
lines required different CPPs. The conformation of the CPP’s C-terminus also played a 
crucial role for an effective translocation of the KLA peptide over the cell membrane. 
3.5.3. Activity of the CPP-Delivered Pro-Apoptotic KLA Peptide 
To evaluate the activity of the pro-apoptotic KLA peptide introduced by MPG, integrin 
or penetratin, the MTT-test was utilised to assess the cell viability using the same 
conditions as in the KLA delivery experiments (Figure 10, page 49). A value of 100 % 
corresponds to no cytotoxic effect of the peptides and viable cells, whereas values lower 
than 80 % viability represent a cytotoxic effect. 
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First of all, CPPs and the KLA peptide themselves caused no toxicity in the tested cell 
lines.  
In Cos-7 cells, most combinations of CPPs and KLA did not lower the cell viability 
significantly (Figure 10A). A detectable pro-apoptotic effect with a cell viability 
reduction of 32 % (P < 0.001 versus KLA alone) was only observed with the 
combination of 10 µM Int-COOH and 20 µM KLA. 
In MCF-7 cells, seven out of the twelve different applied conditions show a reduction in 
cell viability although using 10-fold lower concentrations than in Cos-7 cells 
(Figure 10B). The highest effects were given by MPG-COOH:KLA (1:2) and 
MPG-CONH2:KLA (1:2) with reductions of 32 % (P < 0.001 versus KLA alone) and 
42 % (P < 0.001 versus KLA alone), respectively. This is in agreement with the results 
of the cellular uptake, where both were amongst the combinations with the highest 
delivery rates. 
In RAW 264.7 cells, the toxic effects of KLA delivered by different CPPs and changing 
ratios were not as obvious as in MCF-7 cells. Using the same condition as applied for 
the MCF-7 cells (MTT detection after 3 days), no pro-apoptotic effect could be 
observed for any of the used mixing partners (Annex - Figure 15). Therefore, the 
toxicity of the KLA peptide was evaluated with reduced periods after peptide 
incubation. Measuring the cell viability directly after peptide incubation, a viability 
reduction of 27 % (P < 0.05 versus KLA alone) with 1 µM MPG-CONH2 + 2 µM KLA 
was determined (Müller et al., 2011); a combination which caused toxicity in MCF-7 
cells as well. Toxicity was also observed using 1 µM Pen-CONH2 + 2 µM KLA with a 
viability reduction of 26 % (P < 0.05 versus KLA alone). 
Cancerous MCF-7 and macrophagic RAW 264.7 cells showed the highest induction of 
apoptosis with MPG-CONH2:KLA (1:2), which was not found in fibroblastic Cos-7 
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Figure 10. Viability after CPP:KLA Incubation.  
Cells were incubated with the CPP:KLA mixture and the cell viability was detected after 3 days (Cos-7 and MCF-7) or directly after peptide 
incubation (RAW 264.7) using the MTT-test. 100 % cell viability corresponds to no toxic effect of the peptides. In Cos-7 cells the mixture of 10 µM 
Int-COOH + 20 µM KLA reveals a toxic effect of 32 % (P < 0.05). The mixture of 1 µM MPG-CONH2 + 2 µM KLA reveals a toxic effect of 42 % 
(P < 0.001) for MCF-7 and of 27 % (P < 0.05 %) for RAW 264.7. Data shown are the mean ± SEM (n=3). 
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To ascribe the viability reductions measured with the MTT tests to pro-apoptotic effects 
of the CPP:KLA mixtures, the nuclear morphology of Cos-7, MCF-7 and RAW 264.7 
cells was observed to detect nuclear pyknosis, which is a sign of cells undergoing 
apoptosis. Cells were treated with the conditions that showed toxic effects in the MTT 
assay and stained with HOECHST 33342 (Figure 11). 
 
 
Figure 11. Nuclear Condensation after CPP:KLA Incubation.  
Cells were incubated with the CPP:KLA mixtures and stained with Hoechst 33342 after 
the indicated time periods. Arrows point to condensed chromatin. Condensed chromatin 
was revealed in cells treated with the conditions that showed toxic effects in the MTT 
tests. The scale bar represents 20 µm.  
Cos-7 cells showed no altered nuclei in the control picture or when incubated with 
MPG-CONH2:KLA (1:2) (no effect in MTT assay), but condensed chromatin was found 
after the incubation with Int-CONH2:KLA (1:2) (white arrows in Figure 11A). In 
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MCF-7 cells nuclear pyknosis was clearly visible after the incubation with 
MPG-CONH2:KLA (1:2) after 2 days and even more pronounced after 3 days 
(Figure 11B). When incubating RAW 264.7 cells with MPG-CONH2:KLA (1:2), 
degenerated cell nuclei were only detectable at the day of the incubation (Figure 11C), 
but not after 3 days (data not shown). Furthermore, using the Int-COOH:KLA (1:2) 
condition no effect was identifiable, which coincides with the MTT assays. All tested 
conditions showing reduced cell viabilities in the MTT assays were correlated to 
apoptosis as revealed by nuclear pyknosis. 
3.5.4. Caspase-3 Detection: No Activation in MCF-7 Cells 
In respect to the treatment of cancer, a main goal was to deliver the pro-apoptotic KLA 
peptide in breast adenocarcinoma cells. The induction of apoptosis mainly results in the 
activation of caspases and finally in DNA fragmentation. Previously it has been 
reported that the KLA peptide activates caspase-3 in cell-free systems (rat liver 
mitochondria in cytosolic extracts of DMECs) (Ellerby et al., 1999). On that account, 
the identification of caspase-3 activity by measuring its substrate specific cleavage was 
promoted (Caspase-3 Fluorescence Assay Kit, Cayman) or its activation by self-
proteolysis or cleavage by other upstream caspases (western blot using cleaved-
caspase-3 antibody) in MCF-7 cells. Unfortunately, there was no caspase-3 activity 
detectable with both assays even with different incubation periods (partly shown in 
Figure 12A). 
To confirm the functionality of both assays, Cos-7 cells were used as reference and also 
to show that both methods can be used to detect activated caspase-3.  
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Figure 12. Caspase-3 Detection after the Incubation with CPP:KLA. 
(A) Cleaved caspase-3 detection by western blot: Cos-7 and MCF-7 cells were 
incubated with the peptides (1 hour or 3 hours) and cell lysates (directly after or after 
3 days incubation) were subjected to western blot analysis. Antibodies against ß-actin 
(internal control) and cleaved caspase-3 were used. Cleaved caspase-3 was detected in 
Int-COOH:KLA (1:2) treated Cos-7 cells directly after the incubation (0 days) and after 
3 days. All lysates of MCF-7 cells were negative for cleaved caspase-3. 
(B) Caspase-3 activity measurements: Cos-7 cells were treated with the peptides, lysed 
and the given to the specific caspase-3 substrate. A 2-fold increase using 
Int-COOH:KLA-Cy5 (P < 0.001 versus KLA-Cy5 alone) was detected, which could be 
inhibited using N-Ac-Asp-Glu-Val-Asp-CHO as inhibitor (P < 0.05). Cy5-labelling of 
KLA has no effect on caspase-3 activity. Data shown are the means ± SEM (n=3). 
In Cos-7 cell lysates active caspase-3 was not detectable in untreated cells at day 0 and 
3, as well as when incubated with the peptides alone (Figure 12A). After the incubation 
with MPG-CONH2:KLA (1:2) Western blots show no cleaved caspase-3 after 0 and 
3 days. Caspase-3 was only activated by the mixture of Int-COOH:KLA (1:2) at both 
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time points measured. Both results are in agreement with the viability reductions in the 
MTT assay (Figure 10) and nuclear condensation (Figure 11). 
The incubation with the CPP and the KLA peptide alone had no effect on caspase-3 
activation in Cos-7 cells determined by the Caspase-3 Fluorescence Assay Kit 
(Figure 12B). By using the combination Int-COOH:KLA (1:2) we detected elevated 
levels of caspase-3 activity. Curiously, the difference between ratios 1:1 and 1:2 is not 
as pronounced as observed in Figure 9B and Figure 10A. Nevertheless, the activation of 
caspase-3 is specific and could be reversed using the caspase-3 inhibitor (N-Ac-Asp-
Glu-Val-Asp-CHO; P < 0.05). Finally, by using unlabelled KLA peptide co-incubated 
with Int-COOH the caspase-3 activity was not significantly reduced (P > 0.05) showing 
that Cy5-labelling has no influence on the assay procedure. 
However, to determine if apoptosis is induced in MCF-7 cells after MPG-CONH2:KLA 
treatment other methods should be applied (see next section). 
3.5.5. KLA-Peptide Induced Apoptosis 
The mixture MPG-CONH2:KLA (1:2) caused toxicity in MCF-7 cells (MTT test: 42 % 
toxicity) and led to nuclear chromatin condensation. To further investigate this viability 
reduction and to assign it to apoptosis, the annexin V labelling and the detection of 
DNA fragmentation was assessed using the peptide mixture in comparison with the 
apoptosis inducing agent staurosporin (STS) (Liu et al., 2008). Early apoptosis can lead 
to the displacement of phosphatidylserine at the outer cell membrane which can be 
detected by FITC-labelled annexin V staining and analysed by flow cytometry. Co-
staining with propidium iodine (PI) allows the clear determination of apoptotic cells (in 
contrast to necrotic ones). 
MPG-CONH2:KLA treated MCF-7 cells revealed in the annexin V/PI stain the same 
amount of induced apoptosis as compared to STS-treated cells at day 0 (0.5 µM STS: 
50 ± 27 % versus MPG-CONH2:KLA: 41 ± 8 %) and at day 1 (0.5 µM STS: 85 ± 27 % 
versus MPG-CONH2:KLA: 68 ± 22 %) (Figure 13A, page 54). However, the pro-
apoptotic effect of the KLA-peptide on early apoptosis is lost after day 2 (0.5 µM STS: 
124 ± 54 % versus MPG-NH2:KLA: 26 ± 16 %). 
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Figure 13. Apoptosis Detection in MCF-7 Cells. 
(A) Annexin V: 0, 1 and 2 days after the incubation with 0.5 µM STS and MPG-
CONH2:KLA (1:2) MCF-7 cells were stained with annexin V/PI. The percentage of 
apoptotic cells is shown in the right graph. At day 0 and 1, the amount of apoptotic cells 
is equally induced with 0.5 µM STS or with the pro-apoptotic peptide mixture (P=ns). 
(B) DNA fragmentation (ELISA): A quantitative immunoassay using anti-histone/anti-
DNA antibodies was performed after the incubation with the conditions stated in the 
figure. MCF-7 cells show an increase in mono- and oligonucleosomes up to 3 days after 
the incubation with MPG-CONH2:KLA (1:2) (+ 35 % related to 2 µM KLA, P=0.01). 
Apoptotic cell death goes along with the cleavage of double stranded DNA into mono- 
and oligonucleosomes tightly complexed with core histones. To reassure the pro-
apoptotic properties of the MPG-CONH2:KLA (1:2) mixture in MCF-7 cells, DNA 
fragmentation was measured with the Cell Death Detection ELISA kit. The enrichment 
factors of mono- and oligonucleosomes were significantly increased 3 days after the 
incubation with MPG-CONH2:KLA (1:2) compared to just the incubation with 2 µM 
KLA (+35 % increase in relation to 2 µM KLA, P < 0.01; Figure 13B). 
Using annexin V stain and DNA fragmentation assay, signs of early as well as late 
apoptosis in MCF-7 cells were measured induced by the MPG-CONH2:KLA (1:2) 
mixture, which corresponds to the first results of the MTT assays and nucleus 
condensation measurements.  
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4. DISCUSSION 
Successful and effective cellular delivery remains one of the main obstacles in the 
medical field. The use of cell penetrating peptides (CPPs) has become one of the most 
important tools for the internalisation of a wide range of molecules including 
pharmaceuticals (Dietz et al., 2004; Langel, 2011; Sawant et al., 2009). They are 
usually rich in basic amino acid residues and often derived from proteins that are 
involved in signal transduction. Today, due to their high potential to efficiently cross 
membranes and transport cargoes, characterising and optimising CPPs has been a major 
goal of many different studies (Fotin-Mleczek et al., 2005; Gupta et al., 2005; 
Torchilin, 2007).  
For that reason, defined experimental conditions should be established for the 
measurements of cellular CPP uptake, a necessary step for reproducibility and avoiding 
artefacts. Approximately 100,000 cells per millilitre (depending on the cell line) should 
be seeded one day before the experiment in order to reach about 80 % confluence on the 
day of measurement (12-well plates). Within one experiment, the same number of cells 
should always be seeded, since the uptake of CPPs depends on the peptide to cell ratio 
(Hallbrink et al., 2004). In general, cells should not reach the confluent state to assure a 
complete internalisation without any hindrance by tight junction formation. For 
example, endocytotic internalisation was remarkably reduced especially in confluent 
Madin-Darby canine kidney (MDCK) epithelial cells. This effect was shown to be 
compound-unspecific, since other compounds (FITC-dextran, Tetramethylrhodamine 
isothiocyanate (TRITC)-transferrin etc.), known to be internalised by endocytosis, lost 
their internalisation efficiency (Foerg et al., 2007). Also, trypsinisation or trypan blue 
quenching (depending on the method of measurement) after CPP incubation is required 
to avoid the measurement of external, membrane-bound CPPs. Finally, to acquire 
images for confocal microscopy, the cells should be viable (not fixed) due to the fact 
that formaldehyde or methanol fixation leads to cellular redistribution of the CPPs. 
Toxic effects should be kept at a minimum if CPPs are used as drug delivery vehicles. 
For that reason and deduced from literature, for uptake experiments a final CPP 
concentration of 1 µM to 10 µM was used and an incubation time of 30 minutes. 
To understand the mechanism(s) of cellular CPP uptake better, specific endocytotic 
pathways, the acidification or fusion of endosomes or all energy-dependent uptake 
routes can be specifically and individually blocked. The internalisation rates of the 
tested CPPs was mostly uninfluenced and never completely shut down, but sometimes 
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depending on CPP and cell line significantly reduced or even increased. Since CPPs 
often use different routes of uptake simultaneously (Letoha et al., 2003), the blocking of 
one pathway might have resulted in the internalisation via a different route. However, at 
low concentrations (1 µM to 10 µM) CPPs seem to internalise via endocytosis (Abes et 
al., 2006; Duchardt et al., 2007). Unfortunately, combinations of different endocytosis 
inhibitors are toxic for the cells, making clear conclusions difficult. To fully understand 
internalisation pathways of the used CPPs, different techniques such as light scattering, 
microscopy (electromagnetic spectrum and atomic force microscopy), optical 
spectroscopies (circular dichroism, fourier transform infrared, fluorescence and rapid 
kinetics) in association with investigations dealing with peptide-lipid interactions 
(monolayer and langmuir films) need to be used (Deshayes et al., 2005; Morris et al., 
2008). 
4.1. Comparison of 22 CPPs in Seven Different Cell Types 
For the delivery of the pro-apoptotic KLA peptide, the best CPP should be chosen. This 
is difficult, since a systematic evaluation of more than 11 different CPPs in more than 
six cell lines has never been done before (El-Andaloussi et al., 2007; Fischer et al., 
2004; Fotin-Mleczek et al., 2005; Maiolo et al., 2005; Sarko et al., 2010; Tunnemann et 
al., 2008; Wender et al., 2000). Therefore, 22 CPPs were evaluated in six cell lines and 
primary cells. The toxicity was analysed first, since it is crucial for the peptides’ future 
use as delivery vehicles. Applying the CPPs for 4 hours at a concentration of 10 µM, no 
cytotoxicity (viability < 70 %) was observed in Cos-7, HEK293, HeLa, MDCK, 
MCF-7, RAW 264.7 and RAEC cells (Annex - Table 5 and Table 7). Only S413PV 
revealed toxic effects at this concentration, which were not detectable in the CSLM 
pictures when using an incubation time of 30 min. At high concentrations toxic effects 
were observed on cell membranes and organelles as shown for transportan. 20-30 % of 
the cells revealed a huge accumulation of transportan (Figure 3, last row), which 
correlated with the vital dye trypan blue staining independently of the cell type. This is 
not surprising, since transportan penetrates the cell membrane by creating short-lived 
pores (Matsuzaki et al., 1996).  
The analytical evaluation of the CPP internalisation in the seven different cell types 
(Cos-7, HEK293, HeLa, MDCK, MCF-7, RAW 264.7, RAEC) resulted in a 
classification into three groups (Figure 2 and Figure 4) of which the first one comprises 
surprisingly the most CPPs: (I) CPPs with low cellular uptake [< 500 SI/mg protein; 
such as hCT(9-32), Tat, Pep-1]; (II) CPPs with medium internalisation (500 – 
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1,000 SI/mg protein; e.g. Rev, S413PV, R9 and integrin); (III) CPPs with high cellular 
uptake (> 1,000 SI/mg protein; MPG, penetratin, MAP and transportan). 
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 Penetratin        
 MAP        
 Transportan        
Footnote: The internalisation of the 22 CPPs in the seven cell types can be classified in 
low (marked white), medium (marked grey) and high (marked black) cellular uptake. 
Even if transportan seems to be the more efficient CPP for all cell types, it should be 
taken into account that it is the most cytotoxic CPP (see Table 5 and Table 7 in the 
annex). 
Altogether breast cancer cells show the highest uptake rates of all tested cells whereas 
MDCK cells show the lowest. 
Comparing the results, some agreements with published reports can be found, but also 
some basic differences. For example, the commonly used CPPs such as penetratin, 
MAP and R9, also show the highest signal intensities in the analytical measurements, 
which is in agreement with the literature. The results of MCF-7 cells coincide with the 
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ones of Sarko et al (Sarko et al.), where the uptake hierarchy is defined by MAP > 
penetratin > R9, although they measured a higher uptake of Tat than of R9. 
Furthermore, lower uptake of Tat compared to penetratin and polyarginines was 
confirmed by different reports (Fischer et al., 2004; Wender et al., 2000) as well as the 
better internalisation of R9 compared to R7 (Tunnemann et al., 2008). 
When looking at the cellular CPP distribution, it was mainly of a punctuated pattern 
throughout the cytoplasm probably resulting from an entrapment of the CPPs in 
endosomes. Some CPPs were also located evenly disseminated in the cytoplasm and 
nucleus such as R9 in Cos-7, MDCK and MCF-7 cells suggesting endocytotic and non-
endocytotic uptake routes (Jiao et al., 2009; Vives et al., 2008). Moreover, it has been 
speculated that often more than one uptake pathway is possible, dependent on factors 
such as the peptide concentration applied, the cell line used, the cargo attached and the 
overall incubation conditions (Jiao et al., 2009; Tunnemann et al., 2008; Walther et al., 
2009). This is in agreement with the measurement of different endocytosis inhibiting 
agents during cellular uptake revealing no distinguishing or mainly weak information on 
the internalisation mechanism [details in Table 3 of (Mueller et al., 2008)]. 
 
To compare the uptake of the seven adherent cell types to a suspension cell line, Julia 
Triebus’ results for the uptake of the 22 CPPs in human T-lymphocytes (Jurkat) are 
presented in Figure 14, page 59 (published in her diploma thesis: Quantitative and 
qualitative analysis of cell penetrating peptides in immune cells, FU Berlin, 2009). 
The classification of the CPPs in the three uptake groups (low, medium and high) is 
completely different in the suspension Jurkat cells. Here, the first group (low uptake: 
mean fluorescence < 2,500) comprises only two CPPs and the control peptide pVEC-
scrambled, whereas eleven CPPs are grouped in the third class (high uptake: mean 
fluorescence > 5,000). Many CPPs classified in the first group in the adherent cells 
show high uptake rates in the suspension cells [e.g. HATF3 or hCT(9-32)], which could 
be due to the larger cell surface area exposed to the CPPs. Surprisingly the uptake of 
transportan is low (2,031 ± 469 mean fluorescence), which used to be high in all the 
other adherent cell types.  
 
4. DISCUSSION  59 
 
Figure 14. CPP Uptake in Suspension Jurkat Cells. 
1×106 Jurkat cells were washed and incubated with 10 µM CF-CPPs for 30 min at 37°C. 
The cells were then washed and treated with trypsin (10 min at 37°C) to avoid the 
measurement of membrane bound, but not internalised CPPs. A total of 10,000 events 
were recorded on a FACS Canto II (BD Biosciences). In each analysis, nonviable (PI+) 
cells have been excluded. The uptake of a given CF-CPP into cells was assessed by the 
change of the median fluorescence of a cell sample treated with the peptide compared 
with an untreated control sample. The results are expressed as the mean change in 
median fluorescence ± standard deviation (n=3). 
Altogether the cellular CPP uptake in suspension cells seems to be extremely different 
compared to the uptake in adherent cells - another proof for the importance to compare 
and select the optimal CPP for the desired application.  
However, predicting cell penetrating properties of CPPs by analysing their primary 
amino acid sequence or the structural conformation is still a great challenge. For 
example, CPPs with similar isoelectric points (pI) show different uptake activities. For 
example, penetratin (pI = 12.31) shows high cellular internalisation in comparison to the 
low activity of poly-P (for sequence see Table 1, page 29) with the same pI value (pI = 
12.30). These results demonstrate that the positive charges of CPPs (pI = 10 - 12), 
which are postulated to be important for the interaction with HSPGs on the cell surface, 
are not always the portal guiding endocytosis (Poon et al., 2007). On the other hand, 
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CPPs with a low pI such as integrin (pI = 5.49) revealed good internalisation, especially 
in HEK293 cells. 
The only point, which can be ruled out, is the correlation of the amino acid order within 
the primary sequence. pVEC’s uptake in HeLa cells was 301 ± 53 SI/mg protein, 
whereas the scrambled version showed practically no uptake (53 ± 9 SI/mg protein). A 
similar effect could be observed with S413PV (ALWKTLLKKVLKA-PKKKRKV) and 
SV40 T antigen (PKKKRKV): only the addition of the N-terminal, cell penetrating 
sequence induces the cell internalisation properties in most cell lines (Mano et al., 
2005). These results imply that the sequence and amphipacity of the CPP plays a more 
important role in cellular uptake than the accumulation of positive charge. However, it 
is also difficult to argue with the three dimensional structure since α-helices (e.g. 
transportan (Lindberg et al., 2001) as well as β-structures (e.g. penetratin (Magzoub et 
al., 2003) are reported to be important for cellular internalisation via membrane 
perturbation. 
4.2. Importance of the C-Terminus 
The analysis of the 22 CPPs in the seven cell types shows the importance of the 
appropriate CPP choice for a distinct application. Based on these results, six CPPs were 
selected, namely Tat, S413PV, R9, penetratin, integrin and MPG for further 
investigations. By trying to optimise their cellular uptake, the influence of the 
C-terminus (-COOH versus -CONH2) on the internalisation was evaluated after the 
determination of the toxicity of CPP-CONH2. The carboxyamidated form heavily 
enhanced the ability of CPP penetration for most, but not all tested CPPs (Figure 6). In 
primary RAEC cells only Int-CONH2 internalised better than its carboxylated form, 
whereas the uptake rates of the other CPPs remained the same. Carboxyamidated CPPs 
are more toxic to the six cell lines than carboxylated CPPs with HeLa cells showing the 
most toxic effects. S413PV-CONH2 caused the most viability reductions, though they 
are not linked to higher internalisation rates. Surprisingly, carboxyamidated CPPs are 
less toxic to primary RAEC cells, but the reduced toxicity of CPP-CONH2 in RAEC 
cells cannot be explained by lower internalisation rates. Tat, being one of the most 
frequently used CPPs, shows again very low uptake rates independent of its C-terminus. 
However, the cellular distribution of the CPPs was not altered in the vast majority of 
cases when changing the C-termini (Figure 7). CPPs were mostly detected in a 
punctuated pattern hinting towards endosomal entrapment. Taken together, depending 
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on the CPP and cell line the C-terminus influences the cellular CPP uptake, toxicity and 
in a few cases the cellular localisation. 
4.3. Delivery of the Pro-Apoptotic KLA Peptide by CPPs 
CPPs are proven vehicles for the intracellular delivery of macromolecules such as 
oligonucleotides, peptides and proteins, low-molecular-weight drugs, nano-particles and 
liposomes (Langel, 2011). Even if there is no “golden rule” for the CPP application, the 
importance of CPPs for controlled and targeted delivery of therapeutic and imaging 
agents is very clear.  
In this study, the delivery of the pro-apoptotic KLA peptide in breast adenocarcinoma 
cells, leukaemic macrophages and fibroblasts using the three best CPPs (MPG, integrin 
and penetratin) was compared and their therapeutic applicability was proven. 
Nowadays, the development and analysis of CPPs conjugated to anti-cancer drugs to 
serve as potential new chemotherapeutic agents becomes the focus of attention. In order 
to offer an alternative to covalent methods, a strategy for the delivery of the pro-
apoptotic KLA peptide (Ellerby et al., 1999) into mammalian cells on the basis of a 
simple co-incubation with the appropriate CPP was proposed. 
After determining the optimal mixing ratios (1:1 and 1:2 of CPP:KLA), a 2- to 3-fold 
enhancement of the KLA uptake was demonstrated (Figure 8A). Unfortunately, a 
general rule for a successful KLA delivery was not perceived; different cell types 
needed different CPPs with different C-termini to deliver the KLA peptide effectively. 
Furthermore, the CPP uptake did not necessarily correlate with the KLA uptake. For 
example, MPG-CONH2 having the highest internalisation properties in all cell lines 
(Figure 6), showed only an improvement of the KLA delivery in RAW264.7 cells 
compared to the other employed CPP:KLA pairs in all other cell lines (Figure 9A). In 
contrast, the Int-COOH:KLA mixture (1:1 or 1:2) revealed the best KLA delivery in 
Cos-7 cells, although Int-COOH alone seemed to have nearly no penetration ability 
(Figure 2). CLSM confirmed the measurements done before; KLA was successfully 
delivered into the cells, but showed mostly a punctuated pattern, which might have been 
due to endosomal entrapment (Abes et al., 2006). Besides, a diffuse KLA-distribution 
was observed probably resulting from an endosomal KLA release (Figure 9B). By 
simply mixing the CPP and KLA peptides, it is highly likely to have had no proper 
complex formation as shown for CPP:ON complexes (Andaloussi et al., 2011) nor a 
formation of aggregates as reported in (Kamei et al., 2008). The KLA peptide was 
presumably endocytosed together with the CPP. Over the last years, it became clear that 
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CPPs are internalised at low concentrations via energy-dependent mechanisms 
(Brasseur et al., 2010). Therefore, it can be assumed that the internalisation of the KLA 
peptide was facilitated by the endocytosis of the CPPs.  
However, by looking at the pro-apoptotic properties of the internalised KLA peptide in 
MTT assays (Figure 10), one combination could be depicted, which was toxic to 
macrophages and cancer cells, but showed no toxicity in fibroblasts. The mixture of 
MPG-CONH2:KLA (1:2) resulted in 42 % toxicity (P < 0.001 versus KLA alone) in 
MCF-7 cells and in 36 % toxicity (P < 0.05 versus KLA alone) in RAW 264.7 cells. 
This is particularly interesting since 10-fold lower concentrations were used as in the 
incubations with Cos-7 cells. For the Cos-7 cells only the combination of 
Int-COOH:KLA (1:2) revealed a reduction in cell viability of 32 %. These results were 
validated when microscopically examining the nuclear condensation, which is a 
hallmark of apoptosis. For the conditions causing toxicity in the MTT-viability 
measurements, a distinguished nucleus condensation in all three cell lines was detected 
(Figure 11). Furthermore, the KLA peptide induced active caspase-3 in Cos-7 cells, but 
not in MCF-7 cells. Contradictory results are presented in the literature, showing the 
detection of active Caspase-3 in MCF-7 cells (Wang et al., 2009; Yang et al., 2006) or 
the lack of caspase-3 due to a deletion in the CASP-3 gene (Janicke, 2009). These 
findings show the importance of apoptosis validation by different methods. Later the 
toxic effects in MCF-7 cells were assigned to apoptosis by annexin V stain and DNA-
fragmentation assay. 
To cross-validate the co-incubation approach, the toxicity of covalently coupled CF-
MPG-KLA was determined in MCF-7 cells. Using the CF-MPG-KLA construct at a 
5 µM concentration, a viability reduction could be clearly detected (39 % toxicity at 
day 0 and 44 % at day 1) - a phenomenon which was not obeserved at a 1 µM 
concentration. Since KLA is not even 1/3 of the CF-MPG-KLA sequence, the effective 
KLA concentration correspond to ~ 1.7 µM which is in the same range as in the co-
incubation of MPG-CONH2:KLA (1:2) (2 µM). These results confirm the non-covalent 
strategy as being as effective as the covalent approach and furthermore hint towards an 
advantage of the co-incubation strategy in an enclosed incubation environment, because 
of its simplicity in its application. 
The comparison with published reports to validate the results is difficult, because the 
internalisation is usually done by a covalent linkage of the KLA peptide to CPPs (Cai et 
al., 2010; Watkins et al., 2009), to homing peptides (Ellerby et al., 1999) or to self 
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assembling fibres (Standley et al., 2010). Nevertheless, in all cases researchers used 
covalent-bound peptide concentrations comparable to this study (1 - 10 µM) (Futaki et 
al., 2001; Pooga et al., 2001; Snyder et al., 2004) or even higher (50 µM in (Dutot et 
al., 2009). By using the simple co-incubation strategy to administrate the KLA peptide 
in a low micromolar range (1 µM CPP + 2 µM KLA) - a pro-apoptotic effect of the 
KLA peptide was obtained ranging between 25 % and 60 %, which is in the same scope 
of induced toxicity as described in the other studies (Cai et al., 2010; Ellerby et al., 
1999; Watkins et al., 2009). 
All together, the simple co-incubation strategy enabled the introduction of the pro-
apoptotic KLA peptide in the carcinoma cell line MCF-7 and in the macrophagic cell 
line RAW264.7, both involved in cancer development and metastasis formation. For 
these cell lines a 36 % and 42 % cell viability reduction was reached, which coincides 
with the effect of KLA covalently coupled to CPPs (Cai et al., 2010; Watkins et al., 
2009) or with KLA nanofibres (Standley et al., 2010) even though much shorter 
incubation times were used. More importantly, this effect was not observable in 
fibroblastic Cos-7 cells even at 10-fold higher concentrations. 
In summary, the co-incubation strategy may hold many benefits such as the 
combinatorial potential of different CPPs with different pro-apoptotic peptides, the use 
of targeting devices and associated cost savings due to shorter peptide sequence. These 
advantages are highly relevant in regard to a therapeutic application of pro-apoptotic 
peptides in cancer treatment. In the case of an occurring resistance to one therapeutic 
peptide, it can be quickly and easily replaced when the mixture is applied. 
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5. CONCLUSION 
Despite the high number of biological applications using CPPs, the precise mechanism 
of entry still appears controversial and certainly requires further investigations. 
Contradictory results are often reported, and could stem from experimental variations: 
e.g. diversity of the CPP sequences, the wide variety of cell lines studied, the differing 
protocols applied to investigate the entry mechanism, etc. 
A comparative screen using 22 CPPs in seven cell types under standardised conditions 
revealed the categorisation of the CPPs by their behaviour into three main groups 
showing high, medium and low cellular uptake. Also, the C-terminus of the CPPs is 
able to influence its uptake, toxicity and sometimes even its sub-cellular localisation. 
Compared to a carboxylated C-terminus, a carboxyamidated enhances the cellular 
uptake often. Furthermore, CPPs are able to deliver a second peptide by a simple co-
incubation. Here as well, the delivery depends on CPP, C-terminus and cell type. Inside 
the cell, the delivered peptide is sometimes, but not always functionally active, here 
shown by the reduced cell viability caused by the pro-apoptotic KLA peptide, which 
was assigned to apoptosis in later tests. The activity of the KLA peptide did not 
correlate with its uptake rates. 
This co-incubation approach represents a huge benefit for the future therapeutic 
utilisation: (I) It is much easier and quicker to co-incubate the appropriate CPP with the 
corresponding therapeutic peptide instead of newly synthesising the chosen set; (II) It is 
possible to change the pro-apoptotic peptide quickly in case resistance occurs. 
These results show the difficulty scientists have when working with CPPs. Which CPP 
is the “best” one for the application? The comparison of different CPPs in the respective 
cell line is advisable whilst taking the C-terminus into account. This is aggravated by 
the fact that a chosen CPP might be perfect in its toxicity and uptake properties, but 
might not show the expected transportation capabilities. Therefore it is recommended to 
always include more than one CPP in the evaluation process. 
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7. ANNEX 
Table 5. Viability Test of 22 CPPs in Cos-7, HEK293, HeLa and MDCK Cells. 
 
Footnote: Measurement of the viability using the CCK-8 solution (Fluka). 100 % shows no influence of the CPPs. Four different CPP 
concentrations were used (1, 10, 25 and 50 µM) for each cell line. The data represent the mean of 3-5 independent experiments ± the standard 
deviation; bold data indicated a viability ≤ 70 %. 
CPPs 1 µM 10 µM 25 µM 50 µM 1 µM 10 µM 25 µM 50 µM 1 µM 10 µM 25 µM 50 µM 1 µM 10 µM 25 µM 50 µM
 pVEC-scrambled 79 ± 24 80 ± 8 90 ± 9 37 ± 8 72 ± 11 78 ± 26 74 ± 19 82 ± 29 103 ± 18 99 ± 15 102 ± 22 76 ± 15 103 ± 7 95 ± 22 94 ± 10 93 ± 10
 Polyomavirus Vp1 106 ± 15 81 ± 9 106 ± 24 89 ± 1 108 ± 26 90 ± 15 97 ± 17 88 ± 16 102 ±  22 88 ± 3 90 ± 4 91 ± 20 95 ± 11 106 ±13 122 ±24 98 ± 11
 poly-P 104 ± 03 106 ± 15 94 ± 21 47 ± 10 87 ± 19 96 ± 23 82 ± 10 80 ± 9 92 ± 18 94 ± 21 92 ± 10 107 ± 20 98 ± 7 97 ± 10 99 ± 8 106 ± 7
 NF-kB 102 ± 05 98 ± 10 67 ± 27 54 ± 25 93 ± 8 111 ± 0 89 ± 3 70 ± 9 103 ± 9 90 ± 12 90 ± 18 95 ± 15 104 ± 12 98 ± 20 102 ± 22 101 ± 11
 SV40 105 ± 17 101 ± 29 103 ± 23 87 ± 14 106 ± 14 88 ± 9 104 ± 20 109 ± 9 87 ± 12 86 ± 6 89 ± 1 86 ± 18 101 ± 2 86 ± 8 102 ± 21 100 ± 6
 HATF3 71 ± 01 83 ± 22 49 ± 16 39 ± 20 80 ± 16 76 ± 5 88 ± 17 81 ± 9 87 ± 15 100 ± 28 101 ± 10 105 ± 27 104 ± 20 102 ± 7 114 ± 15 120 ± 25
 hCT(9-32) 118 ± 21 110 ± 4 111 ± 4 92 ± 10 89 ± 24 89 ± 2 78 ± 12 83 ± 25 95 ± 17 108 ± 10 100 ± 10 96 ± 10 96 ± 1 93 ± 8 102 ± 1 108 ± 13
 SynB1 108 ± 11 86 ± 11 96 ± 21 104 ± 4 109 ± 22 81 ± 17 90 ± 15 80 ± 3 105 ± 16 105 ± 21 87 ± 25 96 ± 25 100 ± 8 102 ± 11 99 ± 8 103 ± 19
 DPV6 97 ± 07 83 ± 9 88 ± 10 93 ± 14 104 ± 20 115 ± 6 134 ± 7 114 ± 1 94 ± 8 92 ± 20 106 ± 16 102 ± 9 112 ± 13 84 ± 10 106 ± 18 117 ± 12
 Tat 105 ± 12 99 ± 6 115 ± 10 93 ± 2 82 ± 15 83 ± 15 90 ± 13 94 ± 8 100 ± 20 80 ± 16 63 ± 22 50 ± 10 100 ± 0 100 ± 5 106 ± 6 100 ± 14
 Pep-1 98 ± 01 97 ± 15 93 ± 19 78 ± 11 87 ± 12 99 ± 1 81 ± 9 91 ± 18 96 ± 15 98 ± 17 104 ± 18 109 ± 27 106 ± 20 104 ± 19 105 ± 10 100 ± 14
 Bac1-15 116 ± 17 91 ± 14 105 ± 2 100 ± 12 88 ± 21 104 ± 9 90 ± 13 73 ± 21 95 ± 15 99 ± 11 81 ± 27 88 ± 23 86 ± 9 89 ± 13 89 ± 11 93 ± 16
 R7 91 ± 12 97 ± 4 93 ± 8 94 ± 7 89 ± 14 84 ± 0 80 ± 9 69 ± 11 97 ± 14 87 ± 17 93 ± 26 97 ± 24 105 ± 7 101 ± 22 103 ± 12 110 ± 16
 pVEC 98 ± 26 91 ± 5 78 ± 9 52 ± 12 79 ± 14 71 ± 18 68 ± 12 52 ± 15 114 ± 26 112 ± 17 116 ± 30 94 ± 24 101 ± 9 102 ± 4 102 ± 4 97 ± 2
 Rev 114 ± 10 101 ± 11 98 ± 3 98 ± 20 94 ± 25 93 ± 26 78 ± 28 26 ± 13 85 ± 7 94 ± 16 74 ± 15 34 ± 0 94 ± 1 100 ± 10 76 ± 12 51 ± 11
 S413PV 97 ± 23 89 ± 17 63 ± 21 12 ± 27 94 ± 9 95 ± 6 50 ± 26 11 ± 17 105 ± 12 64 ± 24 0 0 106 ± 4 33 ± 16 11 ± 1 5 ± 2
 R9 91 ± 19 102 ± 8 108 ± 13 88 ± 17 99 ± 18 89 ± 10 72 ± 22 78 ± 9 92 ± 14 111 ± 1 98 ± 19 73 ± 23 104 ± 15 91 ± 6 81 ± 12 61 ± 25
 Integrin 97 ± 4 119 ± 16 117 ± 12 106 ± 3 76 ± 7 75 ± 1 95 ± 11 105 ± 15 96 ± 1 113 ± 22 98 ± 9 118 ± 25 105 ± 5 110 ± 4 101 ± 0 99 ± 4
 MPG 108 ± 15 101 ± 2 116 ± 5 132 ± 5 97 ± 14 100 ± 17 95 ± 26 118 ± 16 99 ± 17 96 ± 13 111 ± 26 103 ± 15 103 ± 5 102 ± 6 83 ± 9 90 ± 12
 Penetratin 114 ± 10 99 ± 7 110 ± 23 114 ± 11 113 ± 17 141 ± 11 105 ± 25 101 ± 17 94 ± 16 95 ± 22 76 ± 3 72 ± 26 98 ± 5 89 ± 10 112 ± 9 120 ± 19
 MAP 99 ± 25 106 ± 11 55 ± 23 6 ± 7 107 ± 17 110 ± 7 113 ± 3 83 ± 16 92 ± 26 99 ± 19 34 ± 10 6 ± 10 102 ± 1 97 ± 14 66 ± 10 46 ± 14
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Table 6. Effects of Endocytosis Modulators on Cellular Uptake - Raw Data. 
Footnote: The cells were treated with the reagents at the given concentrations and later CPPs (10 µM) were added to the medium. The cells were 
incubated for another 30 min and subjected to quantification (for more details see 2.4 Endocytosis Inhibitor Test). The data represent the mean of 











 Cos-7 37°C 20 ± 5 60 ± 10 34 ± 6 64 ± 11 129 ± 10 95 ± 20 481 ± 132 145 ± 42 51 ± 1 1,411 ± 116 472 ± 114 1,600 ± 393 7,349 ± 18
4°C 18 ± 5 123 ± 22 123 ± 18 197 ± 23 134 ± 118 301 ± 47 217 ± 23 374 ± 66 58 ± 12 614 ± 113 534 ± 138 4,127 ± 479 24,813 ± 115
Chlorpromazine 16 ± 3 77 ± 4 52 ± 20 46 ± 11 49 ± 4 279 ± 47 344 ± 99 144 ± 20 51 ± 23 738 ± 118 975 ± 138 875 ± 98 9,533 ± 592
Chloroquine 20 ± 3 226 ± 43 67 ± 10 190 ± 12 164 ± 24 529 ± 122 320 ± 32 800 ± 212 47 ± 13 1,435 ± 232 718 ± 200 4,309 ± 920 10,109 ± 2,236
Nystatin 16 ± 3 119 ± 16 20 ± 2 23 ± 2 23 ± 5 49 ± 4 479 ± 27 128 ± 38 38 ± 8 507 ± 138 357 ± 27 1,668 ± 61 7,388 ± 1,061
Heparin 20 ± 4 144 ± 23 226 ± 19 255 ± 18 344 ± 31 477 ± 17 208 ± 58 325 ± 28 29 ± 2 377 ± 43 414 ± 43 1,677 ± 119 19,844 ± 5,408
Wortmannin 17 ± 3 41 ± 12 31 ± 9 29 ± 8 30 ± 8 96 ± 18 157 ± 18 99 ± 21 86 ± 8 236 ± 14 386 ± 114 569 ± 57 27,805 ± 4,067
 HEK293 37°C 23 ± 6 42 ± 1 95 ± 21 125 ± 4 189 ± 3 645 ± 145 689 ± 179 713 ± 190 1,638 ± 360 928 ± 171 1,269 ± 137 2,795 ± 677 6,197 ± 799
4°C 19 ± 5 97 ± 26 36 ± 7 34 ± 1 68 ± 7 211 ± 24 135 ± 24 214 ± 44 205 ± 45 1,240 ± 195 798 ± 121 18,761 ± 3,000 18,862 ± 2,919
Chlorpromazine 18 ± 3 204 ± 39 62 ± 12 30 ± 9 36 ± 3 378 ± 99 519 ± 44 477 ± 109 79 ± 14 588 ± 27 1,380 ± 331 1,422 ± 259 8,412 ± 201
Chloroquine 21 ± 4 136 ± 9 64 ± 15 60 ± 16 145 ± 21 438 ± 75 792 ± 121 461 ± 7 1,908 ± 153 783 ± 25 1,084 ± 274 2,210 ± 598 17,034 ± 1,732
Nystatin 19 ± 4 61 ± 6 76 ± 15 47 ± 8 39 ± 5 108 ± 17 984 ± 68 165 ± 8 70 ± 16 571 ± 129 1,042 ± 69 1,949 ± 356 2,589 ± 542
Heparin 20 ± 5 250 ± 16 128 ± 5 150 ± 25 589 ± 154 761 ± 83 362 ± 27 637 ± 76 779 ± 29 2,386 ± 479 324 ± 56 4,661 ± 968 11,838 ± 3,794
Wortmannin 11 ± 3 40 ± 11 59 ± 8 24 ± 5 39 ± 8 117 ± 23 348 ± 4 112 ± 22 930 ± 183 519 ± 102 492 ± 45 552 ± 22 25,970 ± 3,059
 HeLa 37°C 21 ± 4 53 ± 9 81 ± 9 59 ± 11 48 ± 7 715 ± 217 1,052 ± 172 1,409 ± 322 595 ± 35 1,257 ± 160 3,335 ± 831 4,199 ± 361 10,529 ± 1,047
4°C 21 ± 5 63 ± 10 107 ± 24 90 ± 3 104 ± 13 267 ± 56 808 ± 198 839 ± 159 173 ± 40 1,068 ± 209 1,374 ± 326 4,798 ± 304 19,985 ± 4,514
Chlorpromazine 22 ± 4 66 ± 15 32 ± 5 100 ± 15 92 ± 2 113 ± 12 1,017 ± 207 1,774 ± 296 51 ± 23 1,517 ± 361 1,178 ± 175 3,121 ± 216 7,709 ± 1,731
Chloroquine 20 ± 6 154 ± 18 55 ± 9 117 ± 26 215 ± 63 697 ± 104 1,447 ± 305 2,011 ± 339 1,071 ± 313 1,209 ± 270 3,415 ± 51 1,388 ± 379 21,840 ± 4,276
Nystatin 21 ± 6 127 ± 36 43 ± 5 102 ± 17 106 ± 26 502 ± 137 411 ± 98 578 ± 123 859 ± 94 1,396 ± 237 1,294 ± 141 5,534 ± 570 21,635 ± 2,816
Heparin 19 ± 6 328 ± 85 262 ± 74 312 ± 95 405 ± 56 545 ± 115 1,134 ± 123 345 ± 56 61 ± 13 194 ± 18 1,734 ± 424 569 ± 106 14,634 ± 3,406
Wortmannin 17 ± 3 46 ± 2 42 ± 12 27 ± 3 45 ± 4 135 ± 15 780 ± 99 224 ± 44 1,211 ± 221 749 ± 75 597 ± 179 1,084 ± 180 29,113 ± 1,025
 MDCK 37°C 17 ± 5 61 ± 9 28 ± 4 28 ± 5 32 ± 8 65 ± 6 686 ± 110 66 ± 15 274 ± 39 435 ± 59 311 ± 22 839 ± 108 4,637 ± 78
4°C 15 ± 3 55 ± 16 20 ± 3 25 ± 7 45 ± 3 57 ± 12 1,064 ± 153 68 ± 7 96 ± 27 574 ± 78 715 ± 72 245 ± 26 13,036 ± 2,744
Chlorpromazine 19 ± 6 83 ± 7 47 ± 8 40 ± 8 49 ± 6 168 ± 45 650 ± 187 220 ± 62 156 ± 20 706 ± 57 556 ± 98 1,472 ± 436 19,713 ± 1,654
Chloroquine 20 ± 4 51 ± 9 27 ± 3 30 ± 4 26 ± 7 114 ± 7 188 ± 53 81 ± 16 23 ± 7 285 ± 50 359 ± 78 1,430 ± 190 28,270 ± 3,237
Nystatin 18 ± 2 46 ± 13 31 ± 6 26 ± 1 26 ± 4 58 ± 8 1,008 ± 179 63 ± 11 46 ± 6 199 ± 20 936 ± 135 6,618 ± 1,768 6,046 ± 688
Heparin 20 ± 4 62 ± 17 27 ± 3 29 ± 3 53 ± 1 45 ± 13 46 ± 12 144 ± 38 84 ± 25 209 ± 61 549 ± 96 2,691 ± 798 22,499 ± 1,930
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Table 7. Viability Test of 22 CPPs in MCF-7, RAW264.7 and RAEC Cells. 
 
Footnote: Measurement of the viability using the CCK-8 solution (Fluka). 100 % shows no influence of the CPPs. Four different CPP 
concentrations were used (1, 10, 25 and 50 µM) for each cell line. The data represent the mean of 3-5 independent experiments ± the standard 
deviation; bold data indicated a viability ≤ 70 %. 
 CPPs 1 µM 10 µM 25 µM 50 µM 1 µM 10 µM 25 µM 50 µM 1 µM 10 µM 25 µM 50 µM
 pVEC-scrambled  84 ± 10  83 ± 10  88 ± 23 112 ± 12 98 ± 5 103 ± 11 100 ± 11 89 ± 6 95 ± 4 72 ± 18 65 ± 19 65 ± 15
 Polyomavirus Vp1 107 ± 14 101 ± 5 89 ± 8  93 ± 19  94 ± 10  93 ± 10 92 ± 9 94 ± 13 89 ± 8 99 ± 12 106 ± 12 97 ± 4
 poly-P  97 ± 15 101 ± 11  96 ± 21 102 ± 26 112 ± 15 101 ± 5 103 ± 8 102 ± 8 111 ± 15 107 ± 6 91 ± 8 89 ± 23
 NF-kB 105 ± 14 97 ± 4  88 ± 12  91 ± 24  87 ± 10  95 ± 8 96 ± 8 95 ± 13 90 ± 5 70 ± 20 76 ± 19 83 ± 11
 SV40  91 ± 22  96 ± 7  88 ± 10  89 ± 24  98 ± 16  96 ± 10 92 ± 10 94 ± 11 87 ± 18 61 ± 6 75 ± 11 79 ± 17
 HATF3  95 ± 12 101 ± 6 106 ± 21  71 ± 22 102 ± 13  87 ± 15 61 ± 9 52 ± 6 83 ± 12 73 ± 12 73 ± 15 74 ± 13
 hCT(9-32) 101 ± 10 98 ± 8  86 ± 17  84 ± 25 106 ± 12 105 ± 6 96 ± 6 96 ± 9 85 ± 16 73 ± 17 69 ± 18 76 ± 12
 SynB1 105 ± 20 96 ± 8 110 ± 19 100 ± 27 100 ± 22  95 ± 20 86 ± 19 89 ± 17 98 ± 29 97 ± 20 105 ± 32 103 ± 9
 DPV6 86 ± 3 99 ± 8  99 ± 10 127 ± 5 94 ± 4  87 ± 10 86 ± 14 89 ± 15 90 ± 15 110 ± 19 81 ± 24 68 ± 1
 Tat  92 ± 17 105 ± 11  95 ± 17  86 ± 9 88 ± 7 89 ± 9 88 ± 14 88 ± 16 96 ± 15 103 ± 20 91 ± 11 66 ± 15
 Pep-1  94 ± 23 103 ± 10 100 ± 20 113 ± 10  95 ± 13 94 ± 2 92 ± 7 98 ± 7 95 ± 12 103 ± 10 102 ± 15 97 ± 23
 Bac1-15  86 ± 20 106 ± 16 109 ± 24 117 ± 5 97 ± 7 92 ± 7 87 ± 10 90 ± 12 90 ± 22 90 ± 7 89 ± 11 85 ± 19
 R7  97 ± 11 104 ± 3  88 ± 21   84 ± 15 100 ± 8 95 ± 3 88 ± 10 76 ± 1 124 ± 15 134 ± 38 132 ± 33 125 ± 27
 pVEC  97 ± 16 105 ± 8 102 ± 24  129 ± 13 101 ± 9 101 ± 9 98 ± 3 60 ± 6 85 ± 85 65 ± 20 76 ± 11 73 ± 13
 Rev 100 ± 14  96 ± 8  86 ± 25  35 ± 8   98 ± 10  93 ± 4 81 ± 10 62 ± 6 89 ± 4 70 ± 16 67 ± 20 71 ± 18
 S413PV  94 ± 17   56 ± 16 0 0  88 ± 7   72 ± 17 46 ± 8 43 ± 10 103 ± 19 90 ± 18 78 ± 11 66 ± 5
 R9 123 ± 7  98 ± 4 105 ± 17  69 ± 11  99 ± 9 100 ± 2 92 ± 8 90 ± 12 92 ± 4 70 ± 12 65 ± 13 74 ± 9
 Integrin  98 ± 13 104 ± 7 110 ± 3 124 ± 30  98 ± 6  94 ± 3 99 ± 3 95 ± 6 97 ± 6 78 ± 18 90 ± 7 92 ± 11
 MPG 107 ± 18 104 ± 8  99 ± 15 109 ± 32 102 ± 10 103 ± 6 95 ± 13 74 ± 7 83 ± 17 76 ± 11 75 ± 13 79 ± 13
 Penetratin  94 ± 13 103 ± 3 103 ± 29 112 ± 19  87 ± 9 82 ± 11 59 ± 12 52 ± 6 98 ± 9 106 ± 12 98 ± 16 102 ± 8
 MAP  95 ± 14 94 ± 7  77 ± 21 16 ± 4  88 ± 9 76 ± 5 72 ± 17 59 ± 9 105 ± 8 117 ± 36 84 ± 16 22 ± 4
 Transportan 97 ± 5 95 ± 2  90 ± 12   74 ± 16   88 ± 10 82 ± 13 75 ± 14 64 ± 7 86 ± 16 105 ± 27 73 ± 18 51 ± 14
MCF-7 RAW 264.7 RAEC
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Table 8. Toxicity of the Carboxyamidated CPPs. 
Footnote: Measurement of the viability using the CCK-8 solution (Fluka). 100 % shows 
no influence of the CPPs. Four different CPP concentrations were used (1, 10, 25 and 
50 µM) for each cell line. The data represent the mean of 3-5 independent experiments 
± the standard deviation; bold data indicated a viability ≤ 70 %. 
 CPPs
 Penetratin 98 ± 22 95 ± 21 62 ± 19 53 ± 11 79 ± 11 79 ± 11 67 ± 4 65 ± 17
 Tat 93 ± 16 87 ± 15 75 ± 18 78 ± 7 93 ± 20 102 ± 14 101 ± 14 107 ± 24
 S413PV 92 ± 22 93 ± 22 73 ± 20 23 ± 3 84 ± 14 76 ± 14 44 ± 3 35 ± 10
 R9 119 ± 18 99 ± 13 94 ± 18 96 ± 16 81 ± 7 98 ± 21 84 ± 21 51 ± 12
 MPG 100 ± 24 94 ± 6 102 ± 18 92 ± 6 89 ± 5 77 ± 1 75 ± 5 57 ± 4
 Integrin 89 ± 15 99 ± 6 100 ± 7 91 ± 0 87 ± 20 84 ± 19 73 ± 20 57 ± 9
 CPPs
 Penetratin 93 ± 14 86 ± 24 42 ± 5 10 ± 2 93 ± 4 89 ± 8 87 ± 10 87 ± 10
 Tat 71 ± 4 79 ± 24 61 ± 9 48 ± 13 96 ± 6 93 ± 19 98 ± 3 87 ± 10
 S413PV 80 ± 12 39 ± 12 0 ± 0 0 ± 0 95 ± 8 75 ± 13 31 ± 12 0 ± 0
 R9 103 ± 5 76 ± 10 52 ± 13 13 ± 3 110 ± 12 100 ± 18 74 ± 21 53 ± 7
 MPG 85 ± 3 82 ± 13 49 ± 10 39 ± 7 91 ± 18 89 ± 10 73 ± 20 52 ± 10
 Integrin 101 ± 6 125 ± 24 116 ± 26 94 ± 5 97 ± 5 99 ± 5 94 ± 9 66 ± 15
 CPPs
 Penetratin 95 ± 19 96 ± 20 97 ± 24 24 ± 2 99 ± 5 79 ± 4 39 ± 2 30 ± 1
 Tat 114 ± 12 123 ± 20 114 ± 12 88 ± 20 98 ± 4 93 ± 6 94 ± 2 85 ± 12
 S413PV 131 ± 2 65 ± 8 0 ± 0 0 ± 0 92 ± 10 37 ± 3 28 ± 1 29 ± 1
 R9 127 ± 19 90 ± 0 78 ± 9 38 ± 10 97 ± 4 88 ± 3 51 ± 3 31 ± 2
 MPG 111 ± 20 106 ± 31 93 ± 26 76 ± 21 96 ± 5 90 ± 8 58 ± 5 34 ± 2
 Integrin 108 ± 12 105 ± 11 98 ± 11 90 ± 14 97 ± 4 95 ± 5 96 ± 5 89 ± 4
 CPPs
 Penetratin 100 ± 2 96 ± 6 99 ± 6 100 ± 5
 Tat 99 ± 3 95 ± 6 96 ± 3 96 ± 5
 S413PV 94 ± 2 94 ± 2 73 ± 14 0 ± 2
 R9 90 ± 5 90 ± 8 91 ± 5 95 ± 7
 MPG 95 ± 4 92 ± 1 89 ± 4 89 ± 3
 Integrin 108 ± 10 106 ± 9 100 ± 12 103 ± 12
RAEC
1 µM 10 µM 25 µM 50 µM
1 µM 10 µM 25 µM 50 µM 1 µM 10 µM 25 µM 50 µM
MCF-7 RAW 264.7
1 µM 10 µM 25 µM 50 µM
HeLa MDCK
1 µM 10 µM 25 µM 50 µM
Cos-7 HEK293
1 µM 10 µM 25 µM 50 µM 1 µM 10 µM 25 µM 50 µM
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Figure 15. Viability after CPP:KLA in RAW 264.7 Cells Depending on the Incubation Duration. 
CPP and KLA were simultaneously incubated for 1 h with RAW 264.7 cells and cell viability was detected using the MTT-test. 100 % cell viability 
corresponds to no toxic effect of the peptides. The cell viability was measured immediately after peptide incubation and removal of the peptides 
solution (0 days) (A), as well as 1 day (B) or 2 days (C) later. The highest pro-apoptotic effect of the KLA peptide is seen directly after the 
incubation and is probably a short-time effect or due to a fast growth of the remaining unaffected cells. Data shown are the means ± SEM (n=3). 
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